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AT A GLANCE 
The version of California Senate Bill 159 analyzed by 
CHBRP would: (1) prohibit commercial plans and 
policies and CalPERS from placing prior authorization 
or step therapy requirements on the provision of 
medically necessary pre-exposure prophylaxis (PrEP) 
or post-exposure prophylaxis (PEP) to prevent HIV, 
and (2) expand scope of practice to enable 
pharmacists to independently furnish PrEP and PEP 
to all Californians, regardless of insurance status or 
type. 
1. CHBRP estimates that in 2020, all of the 
24.5 million Californians enrolled in state-
regulated health insurance, along with 1.6 
million enrollees in County Organized Health 
Systems (COHS) and 1.4 million enrollees in 
the Medi-Cal fee-for-service (FFS) program 
would have insurance subject to SB 159.  
2. Benefit coverage.  
a. 100% of enrollees have coverage for 
PrEP and PEP without prior 
authorization or step therapy 
requirements at baseline, and therefore 
there would be no change in benefit 
coverage. 
b. At baseline, 0% of enrollees are able to 
obtain PrEP and PEP through a 
pharmacist without a prescription from 
another provider. Postmandate, benefit 
coverage will increase to 100%, 
meaning all enrollees will be able to 
seek PrEP and PEP directly from a 
pharmacist without needing to obtain a 
prescription from another provider.  
c. SB 159 would not exceed essential 
health benefits (EHBs). 
3. Utilization. Utilization of PrEP will increase by 
588 enrollees (from 29,395 at baseline to 
29,982 postmandate) in commercial and 
CalPERS plans and by 180 enrollees (from 
9,000 at baseline to 9,180 postmandate) in 
Medi-Cal. Utilization of PEP will increase by 
121 enrollees (from 6,055 at baseline to 6,176 
postmandate) in commercial and CalPERS 
plans and by an unknown number of enrollees 
in Medi-Cal. 
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4. Expenditures. SB 159 would increase total 
net annual expenditures by $11,802,000, or 
0.0074%, for enrollees with DMHC-regulated 
plans and CDI-regulated policies. This is due 
to a $11,328,000 increase in total health 
insurance premiums paid by employers and 
enrollees due to an increase in utilization of 
PrEP and PEP, adjusted by an increase in 
enrollee expenses for covered benefits. 
5. Medical effectiveness. 
a. There is clear and convincing evidence 
PrEP is effective in preventing HIV 
transmission and lowering the risk of HIV 
among high-risk groups with moderate or 
high adherence. 
b. There is limited evidence that PEP is 
effective in preventing HIV transmission 
following occupational and 
nonoccupational exposures.  
c. There is insufficient evidence to assess 
the impact of prohibiting prior 
authorization or step therapy on 
prescription of and adherence to PrEP or 
PEP.  
d. There is insufficient evidence to assess 
either the ability or inability of pharmacists 
to safely and effectively prescribe PrEP or 
PEP. 
6. Public health.  
a. SB 159 would produce no public health 
impact because carriers have established 
procedures for bypassing prior 
authorization requirements.  
b. In the first year postmandate, the 
additional enrollees using PrEP would 
result in a reduction of 25 new HIV cases. 
An unknown reduction would occur 
among new PEP users.  
7. Long-term impacts. Utilization of PrEP and 
PEP will continue to increase as pharmacists 
obtain the required training and awareness of 
PrEP and PEP increases, eventually leveling 
out over time; therefore, the number of 
enrollees who will avoid contracting HIV will 
increase over time.” 
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CONTEXT 
Pre-exposure prophylaxis (PrEP) is a long-term regimen 
recommended for the population that has repeated, 
intimate exposure to HIV-positive individuals or other high-
risk individuals of unknown HIV status. The only Food and 
Drug Administration (FDA)-approved PrEP therapy is a 
single tablet combination therapy of tenofovir disoproxil 
fumarate and emtricitabine (brand name: Truvada®), 
which was approved by the FDA in 2012.1 PrEP is 
indicated for specific groups practicing high-risk behaviors, 
including a subset of all groups identified: men who have 
sex with men (MSM), heterosexual men and women, and 
persons who inject drugs. 
Post-exposure prophylaxis (PEP) is a short-term, daily 
therapy similar to PrEP. However, this regimen must be 
started within 72 hours of (suspected) HIV exposure and 
is only taken for 28 days. PEP is considered an 
emergency treatment and recommended for those with 
episodic suspected or confirmed exposure such as sexual 
assault survivors, workers with occupational exposure 
(e.g., prison or health care systems), newborn children of 
HIV-positive mothers, MSM, and persons who inject 
drugs. 
BILL SUMMARY  
SB 159 was amended in the Senate on April 1, 2019, 
and again on April 11, 2019. This analysis 
incorporates the amendments made on April 1st. The 
amendments made on April 11th would alter the cost 
and public health impacts of SB 159. 
SB 159 as amended April 1st would: (1) prohibit 
commercial plans and policies and CalPERS from placing 
prior authorization or step therapy requirements on the 
provision of medically necessary PrEP or PEP to prevent 
HIV, and (2) expand scope of practice to enable 
pharmacists to independently furnish PrEP and PEP to all 
Californians, regardless of insurance status or type.  
For pharmacists to independently prescribe PrEP or PEP, 
they must complete a training program that addresses the 
use of PrEP and PEP. Pharmacists must also abide by 
specified requirements, such as screening enrollees for 
HIV, providing patient education, and performing specified 
laboratory tests.  
                                                     
1 Refer to CHBRP’s full report for full citations and references. 
The version of SB 159 as amended on April 11th would 
enable pharmacists to independently furnish the initial 30-
day supply of PrEP and requires pharmacists to refer 
enrollees to primary care providers or clinics for additional 
PrEP prescriptions and the recommended testing and 
education. The bill still enables pharmacists to 
independently furnish PEP and leaves the provisions 
prohibiting prior authorization and step therapy 
unchanged. Additional analysis of these provisions will be 
provided in a forthcoming CHBRP analysis.  
Figure A notes how many Californians have health 
insurance that would be subject to SB 159. 
Figure A. Health Insurance in CA and SB 159 
 
Source: California Health Benefits Review Program, 2019. 
Notes: *Medicare beneficiaries, enrollees in self-insured products, etc. 
IMPACTS 
Benefit Coverage, Utilization, and Cost  
The United States Preventive Services Task Force 
released a draft recommendation that persons at high risk 
of HIV acquisition should be offered PrEP by clinicians 
with an A grade. Should this draft recommendation be 
finalized in 2019, plans and policies will be required to 
provide coverage for PrEP without cost sharing as early 
as 2020. 
Benefit Coverage 
CHBRP found 100% of enrollees subject to SB 159 have 
health insurance that is fully compliant with the provision 
of SB 159 that prohibits prior authorization and step 
therapy for PrEP and PEP. 
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Pharmacists are not currently able to independently 
furnish PrEP and PEP. Therefore, benefit coverage for 
this provision of SB 159 would increase from 0% at 
baseline to 100% postmandate. However, some 
pharmacists working in a collaborative practice agreement 
(CPA) are currently able to furnish PrEP and PEP 
independently to enrollees under the terms of the CPA. 
Utilization 
At baseline, it is estimated there are 29,395 users of PrEP 
and 6,055 users of PEP with commercial and CalPERS 
coverage. Postmandate, CHBRP assumes the projected 
utilization will increase by 2% due to increased access to 
PrEP and PEP directly from a pharmacist. Postmandate, it 
is estimated there would be 29,982 users of PrEP and 
6,176 users of PEP. 
Expenditures 
SB 159 would increase total net annual expenditures by 
$11,802,000, or 0.0074%, for enrollees with Department 
of Managed Health Care (DMHC)-regulated plans and 
California Department of Insurance (CDI)-regulated 
policies. This is due to a $11,328,000 increase in total 
health insurance premiums paid by employers and 
enrollees due to an increase in utilization of PrEP and 
PEP, adjusted by an increase in enrollee expenses for 
covered and/or noncovered benefits. 
Figure B. Expenditure Impacts of SB 159 
 
Source: California Health Benefits Review Program, 2019.  
Medi-Cal 
Medications to treat and prevent HIV/AIDS are mostly 
“carved out” of Medi-Cal managed care and the County 
Organized Health Systems (COHS) into the Medi-Cal fee-
for-service (FFS) program. 
Medi-Cal currently prohibits utilization management 
practices for PrEP and PEP. 
Recent changes to the Welfare and Institutions Code  
enable pharmacists to bill Medi-Cal FFS for services 
associated with the independent furnishing for specific 
categories of prescriptions, such as required counseling, 
lab work, and education. The rate of reimbursement for 
these services is required to be at least 85% of the fee 
schedule for physician services under the Medi-Cal 
program. 
CHBRP estimates that utilization of PrEP will increase 
from 9,000 baseline to 9,180 postmandate (2% utilization 
increase).  The increase in utilization is estimated to 
increase state Medi-Cal expenditures by $1,257,000. 
CHBRP is unable to estimate utilization changes of PEP 
within Medi-Cal due to lack of data. 
CalPERS 
Employer expenditures for CalPERS are expected to 
increase by $249,000 (0.0080%) in the first year 
postmandate. Employer premiums would increase by 
$0.0397 per member per month (PMPM), and employee 
premiums would increase by $0.0076 PMPM.  
Number of Uninsured in California 
Because the change in average premiums does not 
exceed 1% for any market segment, CHBRP would expect 
no measurable change in the number of uninsured 
persons due to the enactment of SB 159. 
Medical Effectiveness 
This medical effectiveness review summarizes findings 
from evidence on: (1) the effectiveness of PrEP and PEP 
in preventing HIV/AIDS, (2) the impact of removing prior 
authorization and step therapy on the likelihood that health 
professionals with prescribing authority will prescribe PrEP 
and PEP, (3) the impact of removing prior authorization 
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and step therapy on uptake and adherence of PrEP and 
PEP, (4) the ability of pharmacists to prescribe PrEP and 
PEP safely and effectively, and (5) any harms or adverse 
events associated with PrEP, PEP, or other HIV 
prevention therapies. 
• There is clear and convincing evidence that PrEP 
is effective in preventing HIV transmission and 
lowering the risk of HIV among users with 
moderate or high adherence.  
• There is limited evidence that PEP is effective in 
preventing HIV transmission following 
occupational and nonoccupational exposures. 
• There is insufficient evidence that prohibiting prior 
authorization or step therapy increases the 
likelihood that health professionals with 
prescribing authority will prescribe PrEP or PEP, 
improve adherence to PrEP or PEP, or improve 
outcomes for people taking PrEP or PEP.  
o However, there is limited evidence that prior 
authorization requirements for medications 
used to treat HIV delay receipt of care. 
• There is insufficient evidence to determine 
whether pharmacists can safely and effectively 
prescribe PrEP or PEP. 
Public Health 
CHBRP estimates SB 159 would produce no public health 
impact because carriers have established procedures for 
bypassing prior authorization requirements. It is possible 
that enrollees encounter prior authorization requirements 
and are not able to obtain the bypass for immediate 
authorization for PrEP. Therefore, it is possible the 
prohibition of prior authorization will enable more enrollees 
to obtain PrEP more quickly.  
In the first year postmandate, CHBRP estimates 768 
additional enrollees will obtain PrEP through pharmacists, 
which would result in a reduction of 25 new HIV cases. 
For the 121 additional enrollees who will obtain PEP 
through pharmacists, a small reduction in the number of 
new HIV cases would be expected as well. This estimate 
is supported by limited evidence that pharmacists are able 
to safely and effectively prescribe PrEP and provide 
related services and that the availability of these services 
from pharmacists will result in an increase in utilization 
(2%) of PrEP and PEP. The increase in utilization is 
dampened by limited adoption of the requirements to 
independently furnish PrEP and PEP by pharmacists and 
pharmacies within the first year postmandate. 
Approximately 38,295 enrollees subject to SB 159 use 
PrEP premandate, far below the population that meets 
criteria for PrEP. Although enabling pharmacists to 
independently furnish PrEP would increase utilization by 
2% in the first year postmandate, utilization could continue 
to increase as more pharmacists take the required 
training. However, barriers such as lack of reimbursement 
for associated services such as patient counseling and lab 
tests could limit future utilization increases. 
Long-Term Impacts 
CHBRP estimates utilization of PrEP and PEP will 
continue to increase as pharmacists obtain the required 
training and awareness of PrEP and PEP increases, 
eventually leveling out; therefore, the number of enrollees 
who will avoid contracting HIV will increase over time. 
Should utilization of PrEP continue to increase, CHBRP 
estimates that SB 159 could alter geographic- and stigma-
related disparities by improving access to PrEP through 
alternative locations.  
However, other factors unrelated to insurance coverage of 
PrEP may limit utilization by PrEP-targeted populations. 
Awareness and knowledge of PrEP remain lowest among 
MSM and transgender women, as well as among blacks 
and Hispanics, the groups that have the highest risk of 
contracting HIV. In order for independent furnishing of 
PrEP by pharmacists to increase utilization, patients need 
to be engaged in HIV prevention and seek PrEP from 
pharmacists.   
Essential Health Benefits and the 
Affordable Care Act 
SB 159 would not require coverage for a new state benefit 
mandate, since PrEP and PEP are already covered 
medications, but instead expands which providers can 
furnish PrEP and PEP and specifies terms of utilization 
management. Therefore, SB 159 appears not to exceed 
the definition of essential health benefits (EHBs) in 
California and would not trigger the ACA requirement that 
the state defray the cost of additional benefit coverage for 
enrollees in qualified health plans in Covered California.  
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ABOUT CHBRP 
The California Health Benefits Review Program (CHBRP) was established in 2002. As per its authorizing 
statute, CHBRP provides the California Legislature with independent analysis of the medical, financial, 
and public health impacts of proposed health insurance benefit-related legislation. The state funds 
CHBRP through an annual assessment on health plans and insurers in California.  
An analytic staff based at the University of California, Berkeley, supports a task force of faculty and 
research staff from multiple University of California campuses to complete each CHBRP analysis. A 
strict conflict-of-interest policy ensures that the analyses are undertaken without bias. A certified, 
independent actuary helps to estimate the financial impact. Content experts with comprehensive 
subject-matter expertise are consulted to provide essential background and input on the analytic 
approach for each report.  
More detailed information on CHBRP’s analysis methodology, authorizing statute, as well as all 
CHBRP reports and other publications are available at www.chbrp.org. 
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Table 1. SB 159 Impacts on Benefit Coverage, Utilization, and Cost, 2020 
  Baseline Postmandate Increase/ 
Decrease 
Percentage 
Change 
Benefit coverage 
 Total enrollees with 
health insurance subject 
to state-level benefit 
mandates (a) 
24,490,000 24,490,000 0 0% 
 Total enrollees with 
state-regulated OPD 
coverage (b) 
23,427,000 23,427,000 0 0% 
 Total percentage of 
enrollees with health 
insurance subject to SB 
159 (b) 
100% 100% 0% 0% 
 Total percentage of 
enrollees with coverage 
for PrEP and PEP 
without prior 
authorization and step 
therapy 
100% 100% 0% 0% 
 Total percentage of 
enrollees able to obtain 
PrEP and PEP directly 
from pharmacist 
0% 100% 100% 100% 
Utilization and unit cost 
 Number of enrollees 
using PrEP 
 29,395   29,982   588  2% 
 Number of enrollees 
using PEP 
 6,055   6,176   121  2% 
 Scripts per user of PrEP  6.002   6.002  0.000 0% 
 Scripts per user of PEP 
(c) 
 10.410   10.410  0.000 0% 
 Average prescription 
drug regime cost per 
user (PrEP and PEP) 
$13,822.24 $13,822.24 $0.00 0% 
 Average number of lab 
tests per user of PrEP 
 3.597   3.597  0.000 0% 
 Average number of lab 
tests per user of PEP 
 2.534   2.534  0.000 0% 
 Average annual cost of 
lab tests per user of 
PrEP 
$139.30 $139.30 $0.00 0% 
 Average annual cost of 
lab tests per user of PEP 
$156.78 $156.78 $0.00 0% 
Expenditures 
Premiums by payer 
 Private employers for 
group insurance 
$86,438,375,000 $86,446,324,000 $7,949,000 0.0092% 
 CalPERS HMO employer 
expenditures (d) (e) 
$3,098,551,000 $3,098,800,000 $249,000 0.0080% 
 Medi-Cal Managed Care 
Plan expenditures 
$28,492,273,000 $28,492,273,000 $0 0.0000% 
 Enrollees with 
individually purchased 
insurance 
$12,045,324,000 $12,047,015,000 $1,691,000 0.0140% 
 Enrollees with group 
insurance, CalPERS 
$14,476,394,000 $14,477,833,000 $1,439,000 0.0099% 
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HMOs, Covered 
California, and Medi-Cal 
Managed Care (d) 
Enrollee expenses 
 For covered benefits 
(deductibles, 
copayments, etc.) 
$14,750,880,000 $14,751,354,000 $474,000 0.0032% 
 For noncovered benefits 
(f) 
$0 $0 $0 0.00% 
Total expenditures $159,301,797,000 $159,313,599,000 $11,802,000 0.0074% 
Source: California Health Benefits Review Program, 2019. 
Notes: Provision of PrEP and PEP are “carved out” of Medi-Cal Managed Care plans and COHS, and are instead provided through 
the fee-for-service program. There are approximately 10,545,000 enrollees in full-scope Medi-Cal in 2020. Although not shown in 
Table 1, CHBRP estimates that utilization of PrEP will increase from 9,000 baseline to 9,180 postmandate (2% utilization increase).  
The increase in utilization is estimated to increase state Medi-Cal expenditures $1,256,539. CHBRP is unable to estimate utilization 
changes of PEP due to lack of data.  
(a) Enrollees in plans and policies regulated by DMHC or CDI aged 0 to 64 years as well as enrollees 65 years or older in employer-
sponsored health insurance. This group includes commercial enrollees (including those associated with Covered California or 
CalPERS) and Medi-Cal beneficiaries enrolled in DMHC-regulated plans.2  
(b) Health insurance that has no OPD benefit or has an OPD benefit not regulated by DMHC or CDI is considered compliant.3  
(c) Occupational PEP may be covered through worker’s comp and therefore would not appear in this claims data. As a result, 
utilization of PEP may be higher on a per-person basis due to the nature of non-occupational exposure and the likelihood of repeat 
exposure. 
(d) Enrollee premium expenditures include contributions by employees to employer-sponsored health insurance, health insurance 
purchased through Covered California, and contributions to Medi-Cal Managed Care. 
(e) Approximately 56.17% of CalPERS enrollees in DMHC-regulated plans are state retirees, state employees, or their dependents. 
About one in five (20.5%) of these enrollees has a pharmacy benefit not subject to DMHC.4 CHBRP has projected no impact for 
those enrollees. However, CalPERS could, postmandate, require equivalent coverage for all its members (which could increase the 
total impact on CalPERS). 
(f) Includes only those expenses that are paid directly by enrollees to providers for services related to the mandated benefit that are 
not currently covered by insurance. In addition, this only includes those expenses that will be newly covered, postmandate. Other 
components of expenditures in this table include all health care services covered by insurance. 
Key: CalPERS  = California Public Employees’ Retirement System; CDI = California Department of Insurance; DMHC = Department 
of Managed Health Care; HMO = Health Maintenance Organizations; OPD=Outpatient Prescription Drug; PEP = post-exposure 
prophylaxis; PrEP = pre-exposure prophylaxis. 
 
    
                                                     
2 For more detail, see Estimates of Sources of Health Insurance in California, available at 
http://chbrp.com/analysis_methodology/cost_impact_analysis.php.   
3 For more detail, see Estimates of Pharmacy Benefit Coverage, available at 
http://chbrp.com/analysis_methodology/cost_impact_analysis.php). 
4 For more detail, see Estimates of Pharmacy Benefit Coverage, available at 
http://chbrp.com/analysis_methodology/cost_impact_analysis.php).   
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POLICY CONTEXT 
The California Senate Committee on Health has requested that the California Health Benefits Review 
Program (CHBRP)5 conduct an evidence-based assessment of the medical, financial, and public health 
impacts of SB 159, HIV Prophylaxis. SB 159 was amended in the Senate on April 1, 2019, and again on 
April 11, 2019. This analysis incorporates the amendments made on April 1st. The amendments made on 
April 11th would alter the cost and public health impacts of SB 159.  
Bill-Specific Analysis of SB 159, HIV Prophylaxis 
If enacted, SB 159 as amended April 1, 2019, would affect the health insurance of enrollees in 
Department of Managed Health Care (DMHC)-regulated plans and California Department of Insurance 
(CDI)-regulated policies, in addition to Medi-Cal beneficiaries receiving benefits through the Medi-Cal 
Managed Care plans, County Organized Health Systems (COHS), and the fee-for-service (FFS) program.  
Bill Language Summary 
SB 159 would: (1) prohibit commercial plans and policies and CalPERS from placing prior authorization or 
step therapy requirements on the provision of medically necessary pre-exposure prophylaxis (PrEP) or 
post-exposure prophylaxis (PEP) to prevent HIV, and (2) expand scope of practice to enable pharmacists 
to independently furnish PrEP and PEP to all Californians, regardless of insurance status or type.  
For pharmacists to independently prescribe PrEP or PEP, they must complete a training program that 
addresses the use of PrEP and PEP.  
A pharmacist can furnish an initial course PrEP if the pharmacist:  
• Screens the patient for HIV and confirms a negative test result or determines the patient has 
recently had a negative HIV test; 
• Provides counseling to the patient on the ongoing use of PrEP consistent with the most recent 
Centers for Disease Control and Prevent (CDC) guidelines, which may include education about 
side effects, adherence to the drug regimen, and the importance of timely testing and treatment, 
and additional topics as applicable; and 
• Documents the services provided in the patient’s health record and notifies the patient’s primary 
care provider. If the patient does not have a primary care provider or refuses to consent to this 
notification, the pharmacist shall provide a list of health care service providers to contact 
regarding ongoing care.  
A pharmacist can renew6 a prescription for PrEP if the pharmacist:  
• Ensures the patient is clinically eligible for use of PrEP consistent with the most recent CDC 
guidelines, which may include providing or determining the patient has received timely testing and 
treatment, as applicable, for HIV, kidney function, hepatitis B and C, sexually transmitted 
infections, and pregnancy for women of child-bearing capacity.  
                                                     
5 CHBRP’s authorizing statute is available at http://chbrp.org/faqs.php. 
6 SB 159 bill language states “refill.” However, pharmacists currently have the authority to refill a PrEP prescription 
that is issued by another provider with prescribing authority. “Renew” refers to the pharmacist’s ability to newly write a 
prescription when an enrollee’s prior prescription expired or they used all of the allowed refills.  
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• Documents the services provided in the patient’s health record and notifies the patient’s primary 
care provider. If the patient does not have a primary care provider or refuses to consent to this 
notification, the pharmacist shall provide a list of health care service providers to contact 
regarding ongoing care.  
A pharmacist can furnish PEP if the pharmacist: 
• Screens the patient and determines the exposure meets the clinical criteria for consideration of 
PEP consistent with the most recent guidelines from the CDC; 
• Provides HIV testing or determines the patient is willing to receive an HIV test; 
• Provides counseling to the patient regarding side effects and adherence to the drug regimen and 
testing; and 
• Documents the services provided in the patient’s health record and notifies the patient’s primary 
care provider. If the patient does not have a primary care provider or refuses to consent to this 
notification, the pharmacist shall provide a list of health care service providers to contact 
regarding follow up care. 
Medi-Cal 
The provision enabling pharmacists to furnish PrEP and PEP also applies to all Medi-Cal beneficiaries 
through alterations to the Welfare and Institutions code. Medications to treat and prevent HIV/AIDS are 
mostly “carved out” of Medi-Cal managed care7 and the County Organized Health Systems (COHS) into 
the Medi-Cal fee-for-service program. Therefore, even though the SB 159 provision prohibiting prior 
authorization and step therapy applies to Medi-Cal Managed Care Plans because they are regulated by 
DMHC, enrollees seeking and obtaining HIV prophylaxis will actually receive benefits through the Medi-
Cal fee-for-service program.  
The full text of SB 159 as amended April 1, 2019, can be found in Appendix A. 
April 11th amendments 
The version of SB 159 as amended on April 11th would enable pharmacists to independently furnish the 
initial 30-day supply of PrEP and requires pharmacists to refer enrollees to primary care providers or 
clinics for additional PrEP prescriptions and the recommended testing and education. The bill still enables 
pharmacists to independently furnish PEP and leaves the provisions prohibiting prior authorization and 
step therapy unchanged. Additional analysis of these provisions will be provided in a forthcoming CHBRP 
analysis. 
Relevant Populations 
Although all health plans and policies regulated by DMHC or CDI would be subject to SB 159, plans and 
policies without a pharmacy benefit would not have to comply with the provision prohibiting prior 
authorization and step therapy. The bill would require compliance from the health insurance of the 23.4 
million enrollees in DMHC-regulated plans or CDI-regulated policies that include an outpatient 
                                                     
7 Some beneficiaries, such as those receiving benefits through the AIDS Healthcare Foundation Medi-Cal Managed 
Care Plan (Positive Healthcare California), receive HIV treatment and preventive medication through Medi-Cal 
Managed Care.  
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prescription drug pharmacy benefit.8 Plans and policies with an OPD benefit that is not regulated by 
DMHC or CDI are considered compliant for this analysis. Enrollees receiving health insurance through 
Medi-Cal Managed Care Plans would have coverage subject to this provision of SB 159, however, as 
mentioned above, medications to prevent HIV are carved out of managed care and are furnished through 
the FFS program.  
Because SB 159 also expands the scope of practice for pharmacists through amendments to the 
Business and Professions Code, the bill would affect all Californians, regardless of whether they are 
enrolled in a DMHC-regulated plan or CDI-regulated policy. However, CHBRP focuses on Californians 
who will have health insurance regulated by the state. If enacted, SB 159 would affect the health 
insurance of approximately 24.5 million enrollees (63% of all Californians). This represents 100% of the 
24.5 million with health insurance regulated by DMHC or CDI. An additional 1.6 million COHS 
beneficiaries and 1.4 million persons receiving benefits through the Medi-Cal FFS program would also be 
impacted by SB 159.  
Interaction With Existing Requirements 
Health benefit mandates may interact and align with the following state and federal mandates or 
provisions. 
California Policy Landscape 
California law and regulations 
Current law requires health insurance coverage of single-tablet combination preventive HIV medications if 
they are as effective as multitablet regimens.9 Plans and policies are prohibited from using utilization 
management practices that rely on a multitablet regimen instead of a single-tablet drug regimen unless, 
consistent with clinical guidelines and peer-reviewed scientific and medical literature, the multitablet 
regimen is clinically equally or more effective and equally or more likely to result in adherence to a drug 
regimen. CHBRP analyzed the impact of these provisions in 2018.10  
Scope of practice for pharmacists is regulated through section 4052 of the Business and Professions 
Code. Pharmacists are currently able to independently furnish:  
• Naloxone hydrochloride;11 
• Hormonal contraceptives;12 
• Prescription medications not requiring a diagnosis that are recommended by the federal Centers 
for Disease Control and Prevention for individuals traveling outside of the United States;13 
• Vaccines listed on the routine immunization schedules recommended by the Advisory Committee 
on Immunization Practice;14 and 
                                                     
8 For more information, see CHBRP’s Estimates of Pharmacy Benefit Coverage in California for 2020, available at 
http://chbrp.com/2019%20Estimates%20of%20Pharmacy%20Benefit%20FINAL%200304.pdf. 
9 H&SC Section 1342.71 and IC Section 10123.193. 
10 CHBRP’s analysis of SB 1021 Prescription Drugs is available at: http://chbrp.org/completed_analyses/index.php.  
11 BPC Section 4052.01. 
12 BPC Section 4052.3. 
13 BPC Section 4052. 
14 BPC Section 4052.8. 
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• Nicotine replacement products approved by the Food and Drug Administration (FDA) for use by 
prescription.15  
The Business and Professions code specifies that for all services listed above, pharmacists must obtain 
additional training approved by the California State Board of Pharmacy and pharmacists must notify the 
patient’s primary care provider or record the information in the patient’s medical record.  
Some pharmacists working in a collaborative practice agreement (CPA) are currently able to furnish PrEP 
and PEP independently to enrollees under the terms of the CPA. Pharmacists operating under a CPA 
may currently initiate or adjust the drug regimen of a patient pursuant to a specific written order or 
authorization made by the individual’s treating prescriber.16 Thus, under existing law, pharmacists can 
currently furnish PrEP and PEP independently if they have a CPA with a patient’s physician.  
Medi-Cal 
As mentioned above, HIV medications are carved out of Medi-Cal Managed Care and COHS, and are 
provided through the FFS program. Medi-Cal currently prohibits utilization management practices for 
PrEP and PEP.17  
Recent changes to the Welfare and Institutions Code18 enable pharmacists to bill Medi-Cal FFS for 
services associated with the independent furnishing of the above listed categories of prescriptions, such 
as required counseling, lab work, and education. The rate of reimbursement for these services is required 
to be at least 85% of the fee schedule for physician services under the Medi-Cal program.  
Similar requirements in other states 
CHBRP is not aware of other states that have passed or introduced laws enabling pharmacists to 
independently furnish HIV prophylaxis medications. However, many states allow pharmacists to furnish 
HIV prophylaxis medications under collaborative practice agreements or under the direction of a licensed 
health care provider, such as a physician or nurse practitioner (NP). New York’s State Board of Regents 
amended scope of practice, effective March 2017, allowing pharmacists acting under a non–patient-
specific standing order from a licensed physician or NP to dispense an initial 7 days of PEP medications 
(New York State Department of Health, 2017).  
Washington enacted a law in 2015 that requires health insurers to recognize pharmacists as billable 
providers, therefore enabling pharmacists to bill for services provided in conjunction with prescriptions.19 
One pharmacy in Seattle, the Kelley-Ross Pharmacy, established a Collaborative Drug Therapy 
Agreement with an HIV specialist physician, which allows trained pharmacists to perform specific 
functions, including initiating and monitoring PrEP in line with national guidelines. 
                                                     
15 BPC Section 4052.9. 
16 BPC Sections 4052.2 and 4052.6.. 
17 Department of Health Care Services (DHCS). 2017. Erroneous Treatment Delays and Denials for HIV PrEP and 
PEP. Available at http://files.medi-cal.ca.gov/pubsdoco/newsroom/newsroom_26539.asp. Accessed on April 7, 2019.  
18 WIC 14132.968. 
19 Chapter 237, 2015 Laws, Washington State.  
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Federal Policy Landscape 
Affordable Care Act 
A number of Affordable Care Act (ACA) provisions have the potential to or do interact with state benefit 
mandates. Below is an analysis of how SB 159 may interact with requirements of the ACA as presently 
exists in federal law, including the requirement for certain health insurance to cover essential health 
benefits (EHBs).20 
Any changes at the federal level may impact the analysis or implementation of this bill, were it to pass into 
law. However, CHBRP analyzes bills in the current environment given current law and regulations.  
Essential Health Benefits 
SB 159 would not require coverage for a new state benefit mandate, since PrEP and PEP are already 
covered medications, but instead expands which providers can furnish PrEP and PEP and specifies 
terms of utilization management. Therefore, SB 159 appears not to exceed the definition of EHBs in 
California and would not trigger the ACA requirement that the state defray the cost of additional benefit 
coverage for enrollees in qualified health plans in Covered California. 
Federally Selected Preventive Services 
The ACA requires that nongrandfathered group and individual health insurance plans and policies cover 
certain preventive services without cost sharing when delivered by in-network providers and as soon as 
12 months after a recommendation appears in any of the following:21 
• The United States Preventive Services Task Force (USPSTF) A and B recommendations; 
• The Health Resources and Services Administration (HRSA)-supported health plan coverage 
guidelines for women’s preventive services; 
• The HRSA-supported comprehensive guidelines for infants, children, and adolescents, which 
include: 
o The Bright Futures Recommendations for Pediatric Preventive Health Care; and 
o The recommendations of the Secretary’s Advisory Committee on Heritable Disorders in 
Newborns and Children; and 
• The Advisory Committee on Immunization Practices (ACIP) recommendations that have been 
adopted by the Director of the Centers for Disease Control and Prevention (CDC). 
                                                     
20 The ACA requires nongrandfathered small-group and individual market health insurance — including, but not 
limited to, QHPs sold in Covered California — to cover 10 specified categories of EHBs. Resources on EHBs and 
other ACA impacts are available on the CHBRP website: http://www.chbrp.org/other_publications/index.php. 
21 More information is available on CHBRP’s website under “Resources”: 
www.chbrp.org/other_publications/index.php. 
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USPSTF released a draft recommendation with an A grade22 that persons at high risk of HIV acquisition 
should be offered PrEP by clinicians.23 Should this draft recommendation be finalized in 2019, plans and 
policies will be required to provide coverage for PrEP without cost sharing as early as 2020.  
Prior Authorization and Step Therapy for PrEP and PEP 
Prior authorization and step therapy are both forms of utilization management practices plans or policies 
may put in place to control costs. Prior authorization is a utilization management tool that requires 
providers to submit documentation of medical need to the health plan for approval of coverage for some 
prescription drugs. Step therapy is a utilization management tool that requires an enrollee to try and fail 
one or more formulary-required drugs prior to receiving coverage for the initially prescribed drug. Step 
therapy protocols usually recommend starting with a drug that is less expensive (generics) and/or has 
more “post-marketing safety experience.” 
Analytic Approach and Key Assumptions 
Currently, Truvada is the only FDA-approved combination, single-tablet medication for use as PrEP and 
PEP. Additionally, the CDC guidelines recommend daily doses of PrEP. Research underway suggests 
that additional forms of PrEP may emerge in the near future, and dosing recommendations for oral PrEP 
may expand to include “on demand” dosing. CHBRP discuses how variations in dosing impact the 
effectiveness of PrEP and PEP but excludes discussion of new modalities because they are not FDA 
approved and would not be available within CHBRP’s projected time frame. Should new combination HIV 
Prophylactic drug therapies come on the market in future years, they would fall under the purview of SB 
159. 
CHBRP has assumed SB 159 would not affect the health insurance of enrollees in plans or policies that 
do not include a pharmacy benefit. Less than 5% of all enrollees in plans and policies regulated by DMHC 
or CDI have no pharmacy benefit through their state-regulated health insurance,24 though the figure is 
higher among commercial and CalPERS enrollees, about 7%. For this analysis, those enrollees are 
considered to have health insurance compliant with SB 159. 
If plans and policies contract with a pharmacy benefit manager (PBM) to provide outpatient prescription 
drug benefits, PBMs would also be required to implement the prohibition of utilization management or 
step therapy protocols for PrEP and PEP.25  
SB 159 enables pharmacists to bill Medi-Cal FFS for services associated with furnishing PrEP and PEP, 
including counseling, laboratory testing, and ongoing monitoring. However, pharmacists are not currently 
able to bill commercial health plans and policies for associated services, and therefore CHBRP assumes 
pharmacists would not receive reimbursement for these additional required services. As is the case when 
a pharmacist provides counseling associated with the furnishing of hormonal contraception, under 
existing law pharmacists can only bill commercial plans and policies for the cost of filling the hormonal 
contraception prescription.  
                                                     
22 An A grade indicates the USPSTF recommends the services and there is high certainty that the net benefit is 
substantial.  
23 USPSTF. Draft recommendation statement: prevention of HIV infection: PrEP. 2018. Available at 
https://www.uspreventiveservicestaskforce.org/Page/Document/draft-recommendation-statement/prevention-of-
human-immunodeficiency-virus-hiv-infection-pre-exposure-prophylaxis. Accessed April 2, 2019.  
24 For more information, see CHBRP’s Estimates of Pharmacy Benefit Coverage in California for 2020, available at: 
http://chbrp.com/2019%20Estimates%20of%20Pharmacy%20Benefit%20FINAL%200304.pdf. 
25 Communication with DMHC and CDI, March 2019.  
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SB 159 requires pharmacists to record the dispensing of PrEP and PEP in an enrollee’s health record. 
However, it is unclear whether this bill requires the recording to take place in an enrollee’s medical health 
record or within the pharmacy record. For pharmacists that operate within a closed system, such as 
Kaiser Permanente, the medical and pharmacy records may be linked and accessible in the internal 
system. However, the requirement for the pharmacist to record the furnishing of PrEP and PEP may 
conflict with an enrollee’s desire for this service to remain unknown to their primary care provider. 
Pharmacists that practice in a community pharmacy may not have the direct capability to record the 
provision of PrEP and PEP in an enrollee’s medical record, other than by notifying the health insurance 
company or the enrollee’s primary care provider.  
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BACKGROUND ON HIV PROPHYLAXIS 
SB 159, as amended April 1st, prohibits commercial plans and policies from placing utilization 
management requirements on combination HIV prophylaxis medications and enables pharmacists to 
independently furnish HIV prophylaxis to Californians. This background section provides contextual 
information for the consideration of the medical effectiveness, cost and utilization, and public health 
impacts. 
Human Immunodeficiency Virus (HIV) 
Human immunodeficiency virus (HIV) attacks the body’s CD4 cells (one type of white blood cell known as 
T cells), which are integral to the body’s immune function. Left untreated, opportunistic infections 
including infection-related cancers, will eventually compromise the health of an individual and lead to 
death. HIV invades and effectively destroys CD4 cells during the virus replication process. The acute HIV 
infection stage (within the first 2 to 4 weeks of exposure, where flu-like symptoms may occur) is a highly 
contagious stage because of a large amount of virus in the body. This is followed by a 
latent/asymptomatic period (lasting up to 10 years if untreated) where the virus replicates at a significantly 
slower rate; however, the individual remains contagious. Acquired immune deficiency syndrome (AIDS) is 
the most serious stage of HIV infection, where the body’s immune system is severely compromised with a 
CD4 count below 200 cells/mm (HHS, 2017).  
There is no cure for HIV/AIDS; however, lifelong, highly active antiretroviral therapy (HAART) stops the 
disease progression by reducing the viral load in the blood stream and enables individuals to maintain a 
functional immune system. Due to the effectiveness of HAART treatments, people living with HIV now 
achieve a life expectancy similar to that of the general population (Antiretroviral Therapy Cohort 
Collaboration, 2017).  
Population at Risk for HIV in California 
The population of interest for this provision is the pool of Californians that meet the Centers for Disease 
Control and Prevention’s indications for PrEP and PEP (CDPH, 2016). In particular, men who have sex 
with men (MSM), transgender women, African Americans, Latinos, and persons who inject drugs have the 
highest prevalence of HIV, and continue to be at highest risk for contracting HIV. 
PrEP population 
The California Department of Public Health, Office of AIDS, estimated that between 221,528 and 238,628 
Californians would meet the criteria for PrEP (CDPH, 2016), which is about double the prevalence of 
people living with HIV in California (132,405 in 2016) (CDPH, 2018). The incidence of HIV (newly 
diagnosed cases) has remained close to 5,000 cases per year (of which 88% are male) since 2012 
(CDPH, 2018). See Table 2 for estimates of Californians at risk of HIV infection who would be candidates 
for PrEP.  
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Table 2. Estimated Number of Californians at High Risk of HIV Infection in California, 2016 
Population 
Estimated Number of Californians With 
Indication for PrEP 
MSM 103,779 – 120,879 
High-risk heterosexuals 105,541 
Persons who inject drugs 12,208 
Total 221,528 – 238,628 
Source: California Health Benefits Review Program, 2019, based on CDPH, 2018.  
Note: Insurance status of this population is unknown; it may include Medi-Cal, privately insured, uninsured, Medicare, and other 
forms of insurance. 
Key: MSM = men who have sex with men; PrEP = pre-exposure prophylaxis.  
PEP population 
CHBRP was unable to find an estimate of the California population at risk of requiring PEP. Identifying the 
population that meets the PEP criteria is challenging to the public health community because, by 
definition, the exposures are periodic, emergency-based, and dispersed among a disparate population. 
Additionally, determining patient PEP uptake and adherence is challenging due to PEP initiation 
potentially occurring in different settings than follow-up visits (i.e., emergency department, or free clinic 
followed by a private physician visit). Frequently, there is a lack of patient follow-up to confirm PEP 
adherence or for confirmatory HIV testing (Ford et al., 2015).  
Medications to Prevent HIV/AIDS 
What Are Pre-Exposure Prophylaxis (PrEP) and Post-Exposure Prophylaxis (PEP)? 
Preventing the transmission of HIV to the HIV-negative population has been the focus of a concerted U.S. 
public health effort for more than 30 years. Pre-exposure prophylaxis (PrEP) and post-exposure 
prophylaxis (PEP) are two relatively new additions to the public health prevention toolbox, which also 
includes education, needle exchanges, and condom programs. Both strategies involve using anti-
retroviral medications that prevent HIV from penetrating the CD4 cells. By protecting the cells, these 
medications eliminate the ability of HIV to replicate and destroy the immune system. The drug 
compounds used in PrEP and PEP regimens also may be used as part of HAART for people living with 
HIV. See Table 3 for summary comparison. 
PrEP 
PrEP is a long-term regimen recommended for the population that has repeated, intimate exposure to 
HIV-positive individuals or other high-risk individuals of unknown HIV status. The only FDA-approved 
PrEP therapy is a single tablet combination therapy of tenofovir disoproxil fumarate and emtricitabine 
(brand name: Truvada®), which was approved by the FDA in 2012. PrEP users are instructed to take a 
single tablet once per day as long as they remain in circumstances where HIV exposure is likely to occur. 
PrEP is indicated for specific groups practicing high-risk behaviors, including a subset of: MSM,26 
heterosexual men and women27; and persons who inject drugs if they share needles and/or have high risk 
                                                     
26 Subset of MSM recommended to use PrEP includes adult men without acute or HIV-established infection, with 
male sex partners in past 6 months, not in a monogamous partnership with a HIV-negative man, AND at least one of 
the following: any anal sex without condoms or STI diagnosed in past 6 months (USPHS, 2018). 
27 Adult without acute or HIV-established infection, any sex with opposite sex partners in the past 6 months, not in a 
monogamous partnership with recently tested HIV-negative partner, AND at least one of the following: a man who is 
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partners28 (USPHS, 2018). Providers may prescribe only tenofovir disoproxil fumarate for certain 
subpopulations with drug–drug contraindications (e.g., women taking oral contraceptives, or persons who 
inject drugs on medication-assisted therapy) due to its effectiveness among these subpopulations. 
Practice guidelines for PrEP, updated by the U.S. Public Health Service in 2017, recommend that 
providers perform an HIV risk-behavior assessment using approved questions and baseline HIV test, and 
prescribe a PrEP regimen for those patients at high risk for HIV. 
PEP 
PEP is a short-term, daily therapy similar to PrEP. However, this regimen must be started within 72 hours 
of (suspected) HIV exposure and is only taken for 28 days. In combination with the single tablet, 
Truvada®, adult patients also take another drug such as raltegravir (twice) or dolutegravir (once) daily. 
PEP is considered an emergency treatment and recommended for those with episodic suspected or 
confirmed exposure such as sexual assault survivors, workers with occupational exposure (e.g., prison or 
health care systems), newborn children of HIV positive mothers, MSM, and persons who inject drugs. 
PEP is not routinely recommended for HIV-negative individuals practicing high-risk behaviors; frequent 
PEP treatment may increase an individual’s resistance to HAART, thus making the management of HIV 
more difficult should they seroconvert (CDC, 2018c). See Table 3 for a summary comparison of PrEP and 
PEP.  
There are several national clinical practice guidelines for PEP, in addition to the 2014 World Health 
Organization guidelines (Ford et al., 2015). In the United States, the Centers for Disease Control and 
Prevention issued PEP guidelines for nonoccupational exposure (nPEP) and the U.S. Public Health 
Service issued guidelines for occupational exposure (oPEP) (CDC, 2018e; Kuhar et al., 2018). Each 
guideline recommends a different HIV-risk assessment tool (e.g., health care workers are at lower risk for 
contracting HIV from an occupational needle stick than an individual exposed to HIV through receptive 
unprotected anal intercourse). However, once risk is deemed high enough for treatment (according to 
exposure status), the recommended PEP treatments are the same for occupational and nonoccupational 
exposures (CDC, 2018e).  
  
                                                     
behaviorally bisexual, infrequently uses condoms during sex with 1 or more partners of unknown HIV status who are 
persons who inject drugs or are bisexual male partner, is in an ongoing relationship with an HIV-positive partner, or 
STI diagnosed in past 6 months. 
28 Adult without acute or established HIV infection, any injection of drugs not prescribed by a clinician in past 6 
months AND at least one of the following: any sharing of injection drug equipment in past 6 months or risk of sexual 
acquisition of HIV. 
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Table 3. Summary of PrEP and PEP Regimens for the Prevention of HIV Infection 
Source: California Health Benefits Review Program, 2019, based on CDC, 2017; USPHS, 2018; and PTPWPPT, 
2018. 
Key: PWID = persons who inject drugs; STI = sexually transmitted infection. 
 
Provider Awareness of and Willingness to Prescribe PrEP 
Provider awareness of and willingness to prescribe PrEP is equally important to patient uptake of the 
regimen (Tuller, 2018). A 2015 survey of 1,501 U.S. clinicians (36% family/general practitioners, 31% 
internists, 17% nurse practitioners, and 17% obstetrician/gynecologists) found that 22% of clinicians had 
read the CDC guidelines for PrEP and that 79% were willing to prescribe PrEP to a negative partner in an 
HIV discordant couple (61% for couples planning to conceive); 66% were willing to prescribe for MSM; 
63% for persons who inject drugs, and 34% for patients diagnosed with a sexually transmitted infection 
(STI). The participating clinicians had limited knowledge of PrEP with more than 50% of true/false 
questions receiving an incorrect or “don’t know” response (Smith et al., 2016). 
HIV Pre-Exposure Prophylaxis (PrEP) HIV Post-Exposure Prophylaxis (PEP) 
Reasons for Initiation Reasons for Initiation 
PrEP is recommended for seronegative persons, 
before possible exposure, who think they may have 
repeated exposure to HIV. Examples of situations 
meeting this standard include for protection of HIV-
negative partner in serodiscordant couples; MSM 
with multiple partners, sex workers, and PWID who 
share needles. 
CDC recommends using PEP only in emergency 
situations if HIV exposure is suspected. Examples of 
events meeting this standard include sexual intercourse 
or shared use of drug equipment with a (suspected) 
HIV-positive person, newborns born to HIV-positive 
mothers, cases of sexual assault, condom failure, or 
occupational transmission to health care workers.  
Preferred regimens Preferred regimens 
 Preferred regimen is a combination therapy 
in a single pill (tenofovir disoproxil fumarate), 
and emtricitabine (Truvada®) taken once 
daily for as long as the patient has intimate 
exposure to HIV-positive individuals.  
 For adults: Truvada® (once daily) with 
raltegravir (twice daily) or dolutegravir (once 
daily) as, initiated within 72 hours of suspected 
exposure and continued for 28 days.  
 
 Newborns: zidovudine for 4 weeks (low risk) or 
zidovudine and lamivudine for 6 weeks (high 
risk with untreated HIV-positive mother) initiated 
as close to birth as possible (6–12 hours). 
Concurrent care recommended Concurrent care recommended 
Baseline HIV test; quarterly blood panels for 
Truvada® refill authorization, pregnancy test, HIV 
test or risk assessment, and adherence; blood tests  
every 3 months for kidney/liver effects and STI tests; 
annual appointments to evaluate effectiveness and 
adherence to therapy protocol. 
Baseline HIV test; follow-up appointment with HIV test; 
counseling on risk behavior reduction. 
Effectiveness Effectiveness 
With proper PrEP adherence, risk of HIV infection 
may be reduced by 92% for MSM, 90% for 
heterosexual men and women, and by 70% for 
PWID. 
Most effective when initiated as close to exposure as 
possible. Not effective if started after 72 hours of 
exposure. 
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One barrier to pharmacists currently prescribing PrEP or PEP is lack of knowledge. Studies have found 
that among surveyed pharmacists, less than half were knowledgeable or familiar with PrEP, and more 
than three-quarters indicated they did not have or were unsure if they had sufficient knowledge to counsel 
patients with a PrEP prescription (Broekhuis et al., 2018; Okoro and Hillman, 2018). Okoro and Hillman 
(2018) found that pharmacists' primary concerns with implementing PrEP initiatives were with identifying 
appropriate candidates (19.5%), patient adherence (16.3%), cost (14.8%), and developing antiretroviral 
resistance (12.7%). Broekhuis et al. (2018) found that pharmacists were most concerned about the time 
burden, inadequate compensation for services, and providing services outside of their skill set. 
Pharmacists who receive PrEP training have greater knowledge, more favorable attitudes of PrEP, and 
more prepared and familiar with prescribing guidelines, which is associated with higher confidence in 
PrEP counseling (Meyerson et al., 2019; Przybyla et al., 2019). Following additional training, 54% of 
pharmacists indicated that they were fairly or very likely to provide PrEP services as part of a 
collaborative practice argument with 63% indicating online continuing education as their preferred method 
of learning about PrEP (Balano et al., 2008; Okoro and Hill, 2018).  
Disparities29 and Social Determinants of Health30 in Prevention of HIV/AIDS 
Disparities 
Racial/ethnic disparities 
The CDC’s 2018 analysis of U.S. PrEP prescriptions, prevalence of high-risk behaviors, and HIV 
prevalence found disparities between African American and Latino uptake rates as compared with uptake 
rates of whites (CDC, 2018d). They estimated that 500,000 African Americans and almost 300,000 
Latinos were eligible for PrEP based on CDC clinical guidelines, but 7,000 PrEP prescriptions were filled 
for African Americans and 7,600 PrEP prescriptions were filled for Latinos at retail/mail order pharmacies 
(Smith et al., 2017). Whites experienced a similar unmet need, although the gap was smaller with 42,000 
PrEP prescriptions filled among 300,000 whites who met the CDC guidelines. Limitations to the study 
included no documentation of insurance status and no ascertainment of patient assistance programs 
used, or prescriptions filled through military health systems or closed managed care systems.  
                                                     
29 Several competing definitions of “health disparities” exist. CHBRP relies on the following definition: 
Health disparity is defined as the differences, whether unjust or not, in health status or outcomes within a population. 
Wyatt et al., 2016. 
30 CHBRP defines social determinants of health as conditions in which people are born, grow, live, work, learn, and 
age. These social determinants of health (economic factors, social factors, education, physical environment) are 
shaped by the distribution of money, power, and resources and impacted by policy (adapted from Healthy People 
2020, 2015; CDC, 2014). See CHBRP’s SDoH white paper for further information: 
http://www.chbrp.org/analysis_methodology/docs/Incorporating Relevant Social  Determinants of Health in CHBRP 
Analyses Final to WEBSITE 033016.pdf. 
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Figure 1. Estimated Number of Adults Who Could Potentially Benefit From PrEP, United States, 2015 
 
Source: CDC, 2018d. 
Key: PrEP = pre-exposure prophylaxis. 
 
California’s racial/ethnic disparities in use of PrEP are similar to those reported at the national level. A 
study by Harawa et al. (2018) demonstrates disparities that might also occur among Californians with 
private coverage. It finds that although PrEP uptake by Medi-Cal users was 25 times greater in 2016 than 
in 2012 (9 per million Medi-Cal enrollees in 2012 to 228 per million in 2016), the uptake rate among races 
was varied, with some groups at higher risk having lower uptake rates. For example, the disparity 
between black/African American and white Medi-Cal beneficiaries’ uptake widened between 2013 and 
2016; black/African American uptake increased from 14.6 per million to 282 per million while white uptake 
increased from 16.6 per million to 447 per million. The greatest rate increase occurred among Hispanics 
(who also experience a disproportionate share of HIV infection), but they still had the lowest utilization 
rate (106 per million) in 2016. Uptake rates for Asian and “other” Medi-Cal beneficiaries were 229 per 
million and 306 per million, respectively. This racial/ethnic disparity is present in the general population as 
well with African Americans representing 44% of new HIV infections but 13% of PrEP users; similarly, 
Latinos represented 24% of new infections but 18% of PrEP users while whites accounted for 25% of new 
HIV diagnoses but 62% of PrEP users (Tuller, 2018). CHBRP found no studies identifying racial/ethnic 
disparities in PEP use across the population. 
Sexual orientation/identity 
Of the subpopulations at highest risk for HIV, MSM and transgender women (male-to-female) experience 
high rates of HIV. CDC reports that 22% to 28% of transgender women in the U.S. are living with HIV 
(CDC, 2018a). MSM represent about 2% of the U.S. population, but accounted for 67% of new HIV 
infections in 2016 (CDC, 2018b). Both groups also have been found to have among the lowest rates of 
PrEP initiation and continuation. For example, 761 young California MSM (aged 18 to 29 years) using 
geosocial apps were surveyed about their use of PrEP. Fewer than 10% reported ever taking PrEP, and 
of those who reported ever taking PrEP, 72% reported currently taking PrEP (Holloway et al., 2017). 
CHBRP found no studies identifying disparities in PEP use by sexual orientation. 
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Social Determinants of Health 
Two primary social determinants of health associated with the use of PrEP relate to geographic location 
and stigma: 
Geography  
A small qualitative study sponsored by the California HIV/AIDS Research Centers reported interview 
results from rural county PrEP navigators and AIDS Drug Assistance Program (ADAP) enrollment 
workers. These frontline workers reported that very few providers are educated about or willing to provide 
PrEP in their locales, thus PrEP users have to travel longer distances to receive care. Informants believed 
this barrier reduced PrEP initiation and continuation (Fuller et al., 2018). The Harawa et al. (2018) study 
reported that the disparity in uptake between rural and urban Medi-Cal beneficiaries; rural uptake was 
104 per million beneficiaries and urban uptake was 2.5 times greater (253 per million) in 2016. 
Stigma 
Many PrEP-eligible patients report stigma as a significant barrier to initiating and maintaining PrEP use. 
Some with private insurance seek care through public clinics to avoid (perceived) judgment by their 
private primary care provider, yet the clinics re-refer them to the private provider. The aforementioned 
Fuller et al. (2018) study found that frontline PrEP workers expressed concern that these privately-insured 
individuals denied treatment from the clinic would not initiate PrEP with their private provider. Similarly, 
the frontline PrEP workers observed that individuals with high-deductible health insurance or higher 
incomes are ineligible for patient assistance programs, which was also perceived as a barrier to prompt 
and consistent PrEP use (Fuller et al., 2018).  
Financial barriers 
Individuals with private coverage are more likely able to access PrEP, but many are incurring high out-of-
pocket expenses that makes access and adherence unaffordable (Luthra and Gorman, 2018). In one 
study of young gay and bisexual men, 58.9% of respondents believe they could not afford PrEP, although 
87.2% of participants said they would take PrEP if it were free (Pulsipher et al., 2016). This is likely to 
have a greater impact on individuals who are low-income or uninsured, although the existence of cost-
sharing assistance programs is intended to help mitigate some of these financial barriers to access 
(Smith et al., 2017).  
Societal Impact of HIV/AIDS in California 
The presence of HIV/AIDS in California/the United States creates a societal impact. In dollar terms, the 
societal impact can be indirect (lost wages, etc.) as well as direct (medical care, etc.). CHBRP is unable 
to find data that displays the larger societal impact of HIV/AIDS specifically. The Benefit Coverage, 
Utilization, and Cost Impacts estimates cost impacts on payers, including enrollees. Such figures 
represent a subset of the total societal impact related to HIV/AIDS.  
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MEDICAL EFFECTIVENESS 
As discussed in the Policy Context section, SB 159, as amended April 1st, would authorize pharmacists 
to initiate and furnish pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP) for 
HIV/AIDS, prohibit commercial insurance plans and CalPERS from subjecting coverage of PrEP and PEP 
to prior authorization and step therapy, and expand the Medi-Cal schedule of benefits to include coverage 
for PrEP and PEP services provided by pharmacists. Additional information on HIV/AIDS is included in 
the Background section.  
This medical effectiveness review summarizes findings from evidence31 on: (1) the effectiveness of PrEP 
and PEP in preventing HIV/AIDS, (2) the impact of prohibiting prior authorization and step therapy on the 
likelihood that health professionals with prescribing authority will prescribe PrEP and PEP, (3) the impact 
of prohibiting prior authorization and step therapy on uptake and adherence of PrEP and PEP, (4) the 
ability of pharmacists to prescribe PrEP and PEP safely and effectively, and (5) any harms or adverse 
events associated with PrEP, PEP, or other HIV prevention therapies. 
Research Approach and Methods  
Studies of the effectiveness and potential harms of PrEP and PEP, and the impact of drug utilization 
management techniques on prescription, uptake, adherence, and the safety and effectiveness of 
pharmacist prescribing of PrEP and PEP were identified through searches of PubMed, the Cochrane 
Library, Web of Science, Embase, and Scopus. The website for the Agency for Healthcare Research and 
Quality (AHRQ), an organization that produces systematic reviews and meta-analyses, was also 
searched.  
The search was limited to abstracts of studies published in English and conducted in the United States 
and other developed countries. For studies related to the effectiveness of PrEP and PEP, the search was 
limited to studies published from 2018 to present because CHBRP had previously conducted thorough 
literature searches on these topics in 2018 for SB 1021. Because the analysis of SB 1021 did not address 
the impact of prior authorization or step therapy on prescription of PrEP or PEP, or adherence to PrEP or 
PEP, the search for these studies was limited to 2012 to present. 2012 was chosen as the starting point 
because the FDA-approved Truvada® for PrEP treatment in 2012. The search for articles on the safety 
and effectiveness of provision of PrEP and PEP by pharmacists was also limited to studies published 
from 2012 to present. The literature review also included articles on prior authorization and pharmacist 
prescribing published prior to 2012 that were recommended by the content expert and the peer faculty 
reviewer. 
Of the 557 articles found in the literature search, 27 were reviewed for potential inclusion, and 11 were 
included in the review of medical effectiveness for SB 159. The other articles were eliminated because 
they did not focus on therapies for HIV prevention, were of poor quality, or did not report findings from 
clinical research studies. While reviewing the 27 articles for potential inclusion, 8 articles cited by these 
articles were identified for potential inclusion, and 7 were included in this report. Based on 
recommendations from content experts, an additional 13 articles were reviewed for potential inclusion, 
two of which were included. Eighteen references from CHBRP’s report on SB 1021 were also included in 
this report.  
                                                     
31 Much of the discussion below is focused on reviews of available literature. However, as noted on page 11 of the 
Medical Effectiveness analysis and research approach document (posted here), in the absence of “fully-applicable to 
the analysis” peer-reviewed literature on well-designed randomized controlled trials (RCTs), CHBRP’s hierarchy of 
evidence allows for the inclusion of other evidence. 
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The conclusions below are based on the best available evidence from peer-reviewed and grey literature. 
Unpublished studies are not reviewed because the results of such studies, if they exist, cannot be 
obtained within the 60-day timeframe for CHBRP reports. 
Key Questions 
1. Are HIV prevention therapies (i.e., PrEP and PEP) effective in preventing HIV transmission?  
a. Does the effectiveness of HIV prevention therapies vary at different levels of adherence?  
2. Does prohibiting prior authorizations increase the likelihood that health professionals with 
prescribing authority will prescribe PrEP or PEP?  
a. Does prohibiting prior authorizations improve uptake and adherence to PrEP or PEP 
among potential users?  
3. Does prohibiting step therapy increase the likelihood that health professionals with prescribing 
authority will prescribe PrEP or PEP?  
a. Does prohibiting step therapy improve uptake and adherence to PrEP or PEP among 
potential users?  
4. Can pharmacists safely and effectively prescribe PrEP or PEP? 
5. What are the harms or adverse events associated with PrEP or PEP? 
Methodological Considerations 
CHBRP’s literature review for PrEP focused on Truvada because it is the only FDA-approved therapy for 
PrEP in the United States. Truvada is a single-pill combination of two HIV medications, tenofovir 
disoproxil fumarate (TDF) and emtricitabine (FTC). More recent trials evaluating off-label use of pre-
existing antiretroviral medications for PrEP regimens or new methods of dispensing Truvada, such as 
injections or implantables, are excluded from CHBRP’s review since they are not the standard of care 
recommended in guidelines and have not been approved by the FDA for PrEP. There are no drug 
regimens specifically approved by the FDA for PEP, due to ethical and practical considerations with 
attaining the data necessary to do so. Therefore, CHBRP uses the PEP regimen recommended in the 
2016 United States Public Health Service guidelines for nonoccupational exposures — the most recent 
PEP-related guidelines issued — as the treatment standard for this review (see the Background section 
for more information on guidelines for PrEP and PEP). 
Literature on PEP discusses occupational exposures separately from nonoccupational exposures. 
However, because there is a common body of literature that informs PEP drug selection, the 
recommended regimen and dose for PEP is similar for all risk groups across all major PEP practice 
guidelines relevant to United States populations. Moreover, the evidence base for PEP treatments is 
comprised primarily of studies with lower-quality research designs (i.e., uncontrolled cohorts or case-
control studies) or studies of PEP use in animal models; therefore, the certainty of the conclusions drawn 
from the evidence is limited. For these reasons, CHBRP evaluated treatment effectiveness only for a 
general PEP population; however, the extent to which PEP may be differentially effective due to 
adherence issues between groups is noted when applicable. 
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Additionally, health outcomes such as HIV incidence, risk of contracting HIV, and HIV transmission were 
explored specifically in relation to PrEP and PEP. In other words, the literature search did not focus on 
investigating these outcomes in comparison to other means of HIV/AIDS prevention (e.g., safe sexual 
practices, STI testing, etc.).  
Outcomes Assessed 
The effectiveness of pre-exposure and post-exposure prophylaxis for HIV prevention is assessed using 
the following outcomes:  
1. HIV incidence 
2. HIV risk reduction 
3. HIV transmission 
4. Quality of life  
Adverse outcomes associated with PrEP and PEP, as measured in the literature, included adverse health 
outcomes (e.g., decreased kidney and liver function, loss of bone mass), reproductive outcomes, 
antiretroviral drug resistance, and sexual risk compensation.  
Study Findings32 
Effectiveness of Medications That Prevent HIV/AIDS 
PrEP 
As previously mentioned, this report builds off of the analysis completed for SB 1021. No new randomized 
control trials (RCTs) have been conducted since the writing of this analysis, which identified a systematic 
review and meta-analysis of 14 relevant RCTs and 3 observational studies. Overall, RCTs demonstrated 
a reduction in relative risk of contracting HIV among PrEP users, and observational studies demonstrated 
lower HIV incidence rates among PrEP users compared to no-PrEP controls.  
However, HIV incidence was influenced by adherence. Results from a meta-regression of seven RCTs 
show that adherence to PrEP was a significant moderator of PrEP effectiveness (regression coefficient = 
-0.02, p < 0.0001). The meta-regression also showed higher HIV infection risk reduction among high-
adherence PrEP users compared to intermediate-adherence PrEP users, and that low-adherence PrEP 
users did not receive a protective effect (Fonner et al., 2016). More details about these studies can be 
found in the SB 1021 analysis. Many factors are associated with PrEP adherence. Grant et al. (2014), a 
72-week open-label extension of three RCTs conducted in Brazil, Ecuador, Peru, South Africa, Thailand, 
and the United States (ATN 082, iPrEx, US Safety Study) found that having a known HIV-positive partner 
                                                     
32 The following figures in this section summarize CHBRP’s findings regarding the strength of the evidence for the 
effects of policies regarding PrEP and PEP addressed by SB 159. For test, treatments, and services for which 
CHBRP concludes that there is clear and convincing, preponderance, limited, or inconclusive evidence, the 
placement of the highlighted box indicates the strength of the evidence. If CHBRP concludes that evidence is 
insufficient, a figure that states “Insufficient Evidence” will be presented. 
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was a predictor of adherence (95% CI = 1.05–1.99, p = 0.03). A 48-week demonstration cohort study 
conducted in Brazil by Grinsztejn et al. (2018) found two predictors of long-term adherence: early 
adherence (consistently adhering to the regimen by week 4) to PrEP (95% CI = 1.88–5.65, p < 0.0001), 
and reported sex with HIV-infected partners (95% CI = 1.06–2.94, p = 0.04).  
Researchers have studied several alternatives to standard dosing for PrEP (i.e., one tablet per day) to 
assess their effectiveness in protecting people from HIV. In a double-blind RCT (Molina et al., 2015) and 
an open-label extension of the RCT (Molina et al., 2017), the PrEP intervention consisted of two Truvada 
tablets taken 2 to 24 hours before sex, followed by a third pill 24 hours after the first drug intake and a 
fourth pill 24 hours later. Those engaging in multiple consecutive episodes of sexual intercourse were 
instructed to take one pill per day until the last sexual intercourse, and to then take the two post-exposure 
pills. In the 2015 study, this intervention was associated with a relative risk reduction of 86% (95% CI = 
40–98, p = 0.002) for HIV-1 infection compared to a placebo. In the 2017 study, it was associated with a 
relative risk reduction of 97% (95% CI = 81–100) for HIV-1 infection compared to a placebo. These RCTs 
did not assess the effectiveness of this “on demand” dosing regimen for PrEP relative to daily dosing.  
Researchers have also examined whether alternative dosing regimens are associated with higher rates of 
adherence to PrEP. Maximizing adherence is important because higher adherence to PrEP is associated 
with a lower risk of contracting HIV. A randomized, open-label study conducted in Bangkok, Thailand and 
Harlem, New York City by Grant et al. (2018) found that the feasibility of nondaily dosing differed by study 
site. Participants were randomized to one of three dosing regimens: daily dosing (one tablet daily), time-
driven dosing (one tablet twice weekly with a post-sex dose), or event-driven dosing (one tablet before 
and after sex). In Bangkok, daily and time-driven dosing had comparably high rates of adherence (85.4% 
vs. 79.4%, p = 0.42), whereas the adherence rate for event-driven dosing was slightly lower than both 
(65.1%, p < 0.0001 vs. daily) for men who have sex with men (MSM) and transgender women who have 
sex with men. By contrast, in Harlem, daily dosing had a statistically significant higher rate of adherence 
compared to time-driven dosing (65.1% vs. 46.5%, p < 0.0001) and event-driven dosing (41.3%, p < 
0.0001 vs. daily).  
The literature search identified one study related to the effect of a PrEP regimen on quality of life. 
Kapadia et al. (2018) used data from a RCT of potential PrEP regimens to evaluate the impact of those 
regimens on quality of life (QOL) in at-risk, HIV-uninfected U.S. women and men. The study found that 
there was no significant change in QOL score between the baseline assessment and any time during or 
at the end of the study; in other words, participating in a PrEP regimen did not alter self-perceived quality 
of life. The mean QOL score for women was 0.91 (95% CI = 0.89–0.93) at pre-PrEP baseline and 0.89 
(95% CI = 0.86–0.91) at week 48 (p = 0.29). The mean score for men was 0.95 (95% CI = 0.94–0.96) at 
pre-PrEP baseline and 0.94 (95% CI = 0.93–0.95) at week 48 (p = 0.14). 
 
Summary of findings regarding PrEP for HIV prevention: There is clear and convincing evidence from 
13 fair- and high-quality RCTs and 3 observational studies that PrEP is effective in preventing HIV 
transmission and lowering the risk of HIV among users with moderate or high adherence. A single study 
found that PrEP does not affect self-perceived quality of life. 
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Figure 2. Effectiveness of PrEP for HIV Prevention 
 
PEP 
PEP is a 28-day course of three antiretroviral medications that is initiated within 72 hours of a known or 
suspected exposure to an active HIV infection. CDC guidelines recommend a combination of three 
medications from two drug classes used to treat HIV: nucleoside reverse transcriptase inhibitors (NRTIs) 
and integrase inhibitors. Truvada may be prescribed with raltegravir, an integrase inhibitor, as a PEP 
therapy. However, PEP use is considered off-label use of approved medication for HIV treatment 
because the FDA has not approved the CDC guidelines. 
CHBRP did not identify any new studies about the effectiveness of PEP that were published after the 
report on SB 1021 was issued. The previous literature search found that those exposed to HIV, either in 
occupational or nonoccupational contexts, who took PEP were less likely to contract HIV (Bryant et al., 
2009; Cardo et al., 1997; Schechter et al., 2004; Young et al., 2007). However, Ford et al. (2014) 
observed low PEP completion among occupational and nonoccupational exposures (56%), which Fonner 
et al. (2016) found to be associated with a 45% HIV transmission risk reduction. Adherence to PEP was 
highest among nonoccupational exposures, children, and MSM (Fonner et al., 2016). Although rare, 
several instances of potential PEP failures — defined as HIV seroconversion following timely initiation 
and perfect adherence — have been described in the medical literature. One systematic review and one 
prospective study both determined that PEP failures accounted for 0.04% of seroconversions (Ford et al., 
2014; Thomas et al., 2015). Full details of the previous literature search can be found in CHBRP’s report 
on SB 1021.33. 
 
Summary of findings regarding PEP for HIV prevention: There is limited evidence from a single 
historical case-control study and low-quality observational studies that PEP, as recommended by 
guidelines, is effective in preventing HIV transmission following occupational and nonoccupational 
exposures. Adherence and follow-up in PEP studies is low overall, and therefore limits CHBRP’s ability to 
draw conclusions about the relationship between adherence and effectiveness for PEP as well as the 
frequency of PEP failures. 
 
Figure 3. Effectiveness of PEP for HIV Prevention 
 
 
                                                     
33 http://analyses.chbrp.com/document/view.php?id=1340 
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Impact of Prior Authorization on PrEP or PEP  
CHBRP found no studies that analyzed the impact of prior authorization of PrEP or PEP on use of PrEP 
or PEP or the health outcomes of people who receive these treatments, but did find one study that 
analyzed prior authorizations among patients at an HIV clinic who were prescribed medication to treat 
HIV. The clinic received 288 requests for prior authorization for 144 patients. Thirty-seven (13%) of the 
prior authorization requests were for HIV antiretroviral medications, and 32 (86%) of these were 
approved. All five denials of prior authorization for antiretroviral medications involved fixed-dose 
combinations of medications. In all cases, the health plan denied the authorization because its formulary 
included the single medications present in the fixed dose combinations. Across all types of medication, 
the average length of time to process a prior authorization was 3.1 days; this length of time differed 
between Medicaid (mean time required, 2.1 days) and commercial plans (mean time required, 6.3 days; p 
= 0.034) (Raper et al., 2010). These delays constrained the clinic’s ability to promptly provide life-saving 
medications to people with HIV. Timeliness of receipt of medication is especially important for PEP 
because these medications must be initiated within 72 hours (3 days) of a known or suspected exposure 
to an active HIV infection in order for the drug regimen to have a chance to be effective. 
Summary of findings regarding impact of prior authorization of PrEP or PEP: There is insufficient 
evidence that prohibiting prior authorization increases the likelihood that health professionals with 
prescribing authority will prescribe PrEP or PEP, improve adherence to PrEP or PEP, or improve health 
outcomes for people taking PrEP or PEP. However, there is limited evidence that prior authorization 
requirements for medications used to treat HIV delay receipt of care. It is possible that prohibiting prior 
authorization would enable people to obtain PrEP or PEP more quickly, which is especially important for 
PEP because PEP is only effective if it is initiated within 72 hours of known or suspected exposure to HIV. 
Figure 4. Impact of Prior Authorization on Provision of PrEP and PEP 
 
Impact of Step Therapy on PrEP or PEP  
CHBRP found no studies that analyzed step therapy of PrEP or PEP on use of PrEP or PEP or the health 
outcomes of people who receive these treatments.  
Summary of findings regarding impact of step therapy of PrEP or PEP: There is insufficient evidence 
that prohibiting step therapy increases the likelihood that health professionals with prescribing authority 
will prescribe PrEP or PEP, improve adherence to PrEP or PEP, or improve health outcomes for people 
taking PrEP or PEP.  
Figure 5. Impact of Step Therapy on Provision of PrEP and PEP 
 
Analysis of California Senate Bill 159 
Current as of April 19, 2019 www.chbrp.org 21 
Safety and Effectiveness of Pharmacist Prescribing of PrEP and PEP  
CHBRP identified only one study that documented pharmacists’ ability to prescribe PrEP and PEP safely 
and effectively. Tung et al. (2018) assessed the impact of a newly-implemented pharmacist-managed HIV 
PrEP clinic in Seattle, Washington. In this community pharmacy setting, pharmacists were able to initiate 
and manage Truvada under a collaborative practice agreement with a physician medical director. 
Researchers found high levels of adherence to medications by using mean proportion of days covered 
(PDC) ratio to measure adherence to PrEP. Among the 581 patients who filled their prescriptions at the 
on-site pharmacy and had a reportable mean PDC ratio, 90% had a PDC of more than 80%. 
Furthermore, there were no HIV seroconversions among the 372 patients that actively received 
pharmacist services throughout the duration of the study (March 2015 to February 2018).  
Due to the lack of studies of pharmacist prescribing of PrEP, CHBRP searched for literature on the safety 
and efficacy of pharmacist prescribing of oral contraceptives. CHBRP chose oral contraceptives because 
these medications are also used for prevention and because safe prescribing requires screening potential 
users for health conditions that would contraindicate use (e.g., pregnancy, severe or uncontrolled 
hypertension). One observational study of 26 pharmacists employed by two regional pharmacy chains in 
the Pacific Northwest and 214 women enrollees was identified (Gardner et al., 2008). The pharmacists 
prescribed oral contraceptives under a collaborative practice agreement with a physician. Although the 
pharmacists received 12 hours of training prior to prescribing, the study found that pharmacists made 
inappropriate prescribing decisions for seven women of the 195 women who were prescribed 
contraceptives. Five women had elevated blood pressure at the initial or 3-month visit, and two were 
taking other medications for which use of oral contraceptives is contraindicated. The collaborating 
physician notified the pharmacists to discontinue prescribing oral contraceptives to these women.  All 
seven of these women were recent or current users of hormonal contraceptives, which suggests that the 
study’s exclusion criteria were stricter than the criteria some prescribers use to determine which women 
can safely use oral contraceptives. 
Summary of findings regarding safety and effectiveness of pharmacists prescribing of PrEP or 
PEP: There is insufficient evidence that pharmacists can safely and effectively prescribe PrEP or PEP. 
Only one observational study was identified which found strong adherence to PrEP and no 
seroconversions among people who obtained PrEP from a pharmacist-managed PrEP clinic. In that 
study, pharmacist furnishing of PrEP was conducted under a collaborative practice agreement with a 
physician. 
Figure 6. Ability of Pharmacists to Safely and Effectively Prescribe PrEP and PEP 
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Harms of Medications That Prevent HIV/AIDS  
PrEP  
Adverse events  
Among the 11 trials that evaluated the incidence of serious adverse events (AE), there was no difference 
in the risk of developing serious AEs between participants who received PrEP as compared with placebo 
(odds ratio = 1.02, 95% CI = 0.92–1.13, p = 0.76).  
Kidney: Findings regarding the impact of PrEP on kidney health were inconclusive. Three studies 
reported slight decreases in kidney function among PrEP recipients that resolved after discontinuation of 
PrEP (Martin et al., 2015; Solomon et al., 2016; Tang et al., 2018). Similarly, a systematic review by Chan 
et al. (2018) found that in previously healthy individuals, PrEP was associated with a statistically 
significant but largely reversible decline in kidney function; differences between PrEP and placebo groups 
were resolved after PrEP was discontinued. Additionally, a meta-analysis by Yacoub et al. (2016) 
examined the risk of kidney-related adverse events in 17,222 individuals randomized to receive PrEP, 
and found that most of the kidney-related adverse events were classified as Grade 1, meaning that 
creatinine elevations only reached 1.1 to 1.3 times the upper limit of normal. In contrast, Siguier and 
Molina’s systematic review (2018) cites inconsistent findings between PrEP and placebo groups in 
regards to creatinine levels. Siguier and Molina (2018) also point out that because the studies selected 
patients without underlying kidney disease, poor adherence to PrEP may have resulted in an 
underestimation of the rate of kidney-related adverse events.  
Van Damme et al. (2012), a placebo-controlled RCT of HIV-negative African women, found that drug 
discontinuation rates due to kidney and liver function were higher in the PrEP group (4.7% in the PrEP 
group versus 3% in the placebo group, p = 0.051). However, there were no significant differences 
between the two study groups in grade 3 or higher liver abnormalities or grade 2 or higher creatinine 
abnormalities.  
Bone Mineral Density: Findings regarding the impact of PrEP on bone mineral density were inconclusive. 
Several studies found that PrEP users experienced declines in bone mineral density (BMD) (Kasonde et 
al., 2014; Liu et al., 2011). Siguier and Molina (2018) finds moderate decreases in hip and spine BMD in 
MSM and increased BMD in transgender individuals after 24 weeks (six months) of treatment. Chan et al. 
(2018) finds that while bone mineral density declines with PrEP use, increased bone fractures have not 
been demonstrated, and the changes are reversed after PrEP is discontinued. BMD decline may also be 
greater in adolescent PrEP users who have not achieved peak mass.  
Digestive Tolerability: Siguier and Molina’s systematic review (2018) finds that PrEP users commonly 
experience abdominal pain, diarrhea, nausea, vomiting, and other digestive symptoms in the first few 
weeks of treatment. Based on the studies cited, the time frame within which this “start-up syndrome” is 
resolved ranges from 1 to 3 months. 
Reproductive outcomes  
A systematic review discussed in CHBRP’s report on SB 1021 (Fonner et al., 2016) identified two RCTs 
that assessed the effectiveness of hormonal contraception among women taking PrEP as compared with 
women randomized to placebo. Due to differences in study design, pooled analysis was not possible. 
Analyses of raw data suggested that pregnancies resulting from contraception failures may have been 
higher among PrEP users in both trials (FEM-PrEP: RR = 1.48; Partners PrEP: RR = 1.32). In study 
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subanalyses, however, the observed differences in crude pregnancy rates were attenuated after 
adjustment for contraceptive type, study site, and age (Callahan et al., 2015; Murnane et al., 2014).  
A meta-analysis of adverse pregnancy outcomes, such as fetal loss and preterm birth, among women 
enrolled in these two RCTs showed that pregnancy-related adverse events did not differ between PrEP 
and placebo groups (RR=1.25, 95% CI = 0.64–2.45, p = 0.52). Nor were differences in rates of adverse 
birth outcomes observed when PrEP users were stratified by adherence or PrEP regimen (i.e., Truvada or 
tenofovir-alone) (Fonner et al., 2016).  
Antiretroviral drug resistance  
HIV resistance to first-line HIV medications for treatment, although not a direct harm, is an important 
consideration for high-risk PrEP users because the medications that comprise Truvada are also 
commonly used to treat active HIV infections. Resistance to Truvada, due to long-term low-dose 
exposure during PrEP, could limit a person’s treatment options if they develop a subsequent HIV 
infection. The systematic review CHBRP cited in its report on SB 1021 identified six RCTs that have 
assessed the incidence of drug resistance to antiretroviral medications among participants who 
underwent HIV seroconversion following PrEP use. Overall drug resistance was low, occurring among 
only 2% of the 533 participants who experienced HIV seroconversion across all study arms. In addition, a 
meta-analysis of drug resistance data from these RCTs found that the risk of developing resistance to 
either of the PrEP medications was significantly higher among PrEP users with an undetected pre-
existing HIV infection at enrollment (RR = 3.34, 95% CI = 1.11–10.06, p = 0.03). PrEP use was not 
significantly associated with drug resistance detected among persons who experienced HIV 
seroconversion post-randomization (Fonner et al., 2016). 
Sexual risk compensation  
Sexual activity is one of the primary ways in which HIV/AIDS may be contracted. The theory of risk 
compensation suggests that people behave in response to their perceived level of risk; increases in risk 
lead to more cautious behavior, and the opposite occurs for decreases in risk. Under this theory, 
availability and/or uptake of HIV prophylaxis may cause people at risk for HIV infection to engage in 
riskier sexual practices because they believe that their risk for contracting HIV is substantially lower than 
before. CHBRP identified studies on the impact of PrEP on several measures of sexual risk 
compensation: condomless sex, incidence of sexually transmitted infections, and number of sexual 
partners. 
Condom Use: Findings regarding the impact of PrEP uptake on condom use during sexual intercourse 
were inconclusive. Only one RCT assessed whether condom use was associated with PrEP use. 
McCormack et al. (2016) randomized participants to immediately receiving PrEP or receiving deferred 
PrEP after 1 year. The study found that a larger proportion of participants in the immediate treatment 
group reported receptive condomless anal sex with 10 or more partners at a statistically significant level 
relative to the deferred treatment group (21% vs. 12%, p = 0.03)  
Across non-RCT studies, findings varied substantially. Two cohort demonstration studies found that the 
rate of condomless sex remained stable during the intervention period (Grinsztejn et al., 2018; Liu et al., 
2016). One open-label extension study found that the rate of condomless anal sex decreased (Grant et 
al., 2014). Six prospective cohort studies reported increases in condomless anal sex in response to PrEP 
uptake (Lal et al., 2017; Molina et al., 2017; Montano et al., 2019; Morgan et al., 2018; Oldenburg et al., 
2018; Zablotska et al., 2018).  
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Grov et al. (2018) surveyed MSM about their HIV status, HIV viral load, and PrEP use, as well as that of 
their recent casual male partners. The study found that HIV-negative men on PrEP engaged in 
condomless anal sex most commonly when their partners were also on PrEP, HIV-negative and not on 
PrEP, or HIV-positive with an undetectable viral load.  
Incidence of STIs: Findings regarding the impact of PrEP uptake on incidence of sexually transmitted 
infections (STIs) among PrEP users were inconclusive. Three placebo-controlled RCT studies analyzed 
the impact of PrEP uptake on incidence of STIs (McCormack et al., 2016; Molina et al., 2015; Solomon et 
al., 2014). McCormack et al. (2016) detected no significant differences in rates of STIs among 
participants who received PrEP versus participants who received a placebo, after adjusting for the 
number of screenings participants received. Solomon et al. (2014) measured syphilis prevalence among 
participants in initial screening and follow-up appointments and found no difference in syphilis incidence 
between the PrEP and control groups.   
Three studies found that STI incidence was high, but stable, for participants throughout the course of the 
study; in other words, there were no statistically significant increases in STI rates following initiation of 
PrEP (Liu et al., 2016; Molina et al., 2017; Zablotska et al., 2018). 
Two studies in Seattle, Washington, and Melbourne, Australia, respectively, found significant increases in 
STI diagnoses in the first 12 months after being prescribed PrEP (Lal et al., 2017; Montano et al., 2019).  
Grinsztejn et al. (2018) found that an STI diagnosis of rectal chlamydia, rectal gonorrhea, or incident 
syphilis at the end of the 48-week study intervention period did not have a statistically significant 
relationship with whether one’s dried blood spot lab test showed a protective concentration of tenofovir 
diphosphate at week 48. In other words, achieving a high level of adherence (at least four doses per 
week of tenofovir) did not affect STI incidence.   
Changes in Number of Sexual Partners: There is a preponderance of evidence that PrEP uptake does not 
lead to a difference in the number of sexual partners. Two RCTs indicated no difference, and one RCT 
found a small difference. McCormack et al. (2016) compared participants who were randomized to 
receive immediate PrEP treatment with participants who were randomized to receive deferred PrEP 
treatment after a 1 year waiting period. The authors found no statistically significant difference between 
the two groups at the 1-year mark. Additionally, Grant et al. (2014), an open-label extension of a prior 
RCT, found that the total number of sexual partners decreased during the study follow-up period in both 
the group receiving PrEP and the group not receiving PrEP. In contrast, Molina et al.’s (2015) placebo-
controlled double-blind RCT found a small, but statistically significant, decrease in the number of sexual 
partners within the past 2 months in the placebo group. 
Two other studies found no significant changes in the proportion of participants with regular sexual 
partners (Lal et al., 2017; Zablotska et al., 2018). Zablotska et al. (2018) expanded on this by also finding 
that there was no significant change in the proportion of respondents with multiple regular sex partners. 
Lal et al. (2017) additionally found that throughout the 12-month study follow-up period, the proportion of 
participants reporting sex with casual partners remained stable, and there was no significant change in 
the number of sexual acts with casual partners. Montano et al. (2019) found no change in the reported 
number of sexual partners in the last 30 days between the initial PrEP appointment and the end of the 12-
month study follow-up period. Similarly, Oldenburg et al. (2018) found no statistically significant difference 
in the total number of sexual partners across time (from the initial baseline clinic visit to the 3- and 6-
month follow-up visits).  
Two studies found that the mean number of reported sexual partners decreased in the previous 3 months 
and during the 48-week study follow-up period, respectively (Grinsztejn et al., 2018; Liu et al., 2016).  
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PEP  
Adverse events resulting from antiretroviral medication toxicities are the most common harm associated 
with PEP, and may account for up to 70% of PEP discontinuations and lapses in adherence (Thomas et 
al., 2015). Compared with earlier antiretroviral medications used as PEP, the currently recommended 
regimen (i.e., Truvada plus raltegravir) has the lowest observed discontinuation rate due to adverse 
events (1.9%, 95% CI = 0.0%–3.8%) (Ford et al., 2015). Therefore, the following discussion of adverse 
events is specific to this regimen since it is most likely to be used in clinical practice.  
CHBRP cited two prospective observational safety studies concerning PEP adverse events in its report 
on SB 1021.34  Both studies found that all adverse events were resolved upon completion of PEP. Mayer 
et al. (2012) found that most reported adverse events were of mild-to-moderate grade, and the most 
commonly reported side effects were nausea/vomiting (27%), diarrhea (21%), headache (15%), and 
fatigue (14%). McAllister et al. (2014) reported that during treatment, the most common self-reported side 
effects were mild to moderate fatigue (37%), diarrhea (25%), and nausea (24%). Muscle pain accounted 
for 9% of self-reported adverse events. Elevated levels of alanine aminotransferase were detected in 19% 
of participants, but no cases of clinical hepatitis developed. No other serious adverse events were 
detected.  
Although the two studies met CHBRP’s inclusion criteria and had similar findings, the generalizability of 
these findings to the overall population of PEP users may be limited. Sample sizes were small (i.e., 100 
persons or fewer), made up almost entirely of men, relied primarily on patient self-reporting, and were 
exclusively conducted in nonoccupational settings. 
No studies about sexual risk compensation in response to PEP use were found. 
Summary of Findings  
There is clear and convincing evidence that PrEP is effective in preventing HIV transmission and lowering 
the risk of HIV across all high-risk groups.  
• Effectiveness is moderated by adherence; moderate or high adherence are both associated with 
protective benefits.  
• Participating in a PrEP regimen is not associated with changes in self-perceived quality of life. 
• PrEP is not significantly associated with poor reproductive health outcomes. 
• Findings from studies of the effects of PrEP on kidney function and bone mineral density are 
inconclusive. 
• Resistance to Truvada, due to long-term low-dose exposure during PrEP treatment, may limit a 
person’s treatment options if they develop a subsequent HIV infection and occurs most frequently 
among persons with a pre-existing unknown active HIV infection when they initiated PrEP..   
• Findings regarding the relationship between PrEP and sexual risk compensation (e.g., 
condomless sex, STI incidence, and changes in the numbers of sexual partners) are 
inconclusive.  
                                                     
34 http://analyses.chbrp.com/document/view.php?id=1340 
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There is limited evidence that PEP is effective in preventing HIV transmission following occupational and 
nonoccupational exposures.  
• CHBRP is unable to draw conclusions about the relationship between adherence and 
effectiveness of PEP.  
• PEP failures are rare, and can mostly be attributed to poor adherence, late initiation, and 
repeated exposure to HIV during treatment due to ongoing high-risk behaviors.  
• Serious adverse events associated with PEP are rare and resolve following completion or 
cessation of treatment.  
There is insufficient evidence to assess the impact of prior authorization and step therapy on prescription 
of and adherence to PrEP or PEP.  
There is insufficient evidence to assess the ability of pharmacists to safely and effectively prescribe PrEP 
or PEP.  
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BENEFIT COVERAGE, UTILIZATION, AND COST IMPACTS 
As discussed in the Policy Context section, SB 159, as amended April 1st, would allow pharmacists to 
provide pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP) to prevent HIV for DMHC-
regulated health plans and CDI-regulated policies. SB 159 would also prohibit DMHC-regulated health 
plans and CDI-regulated policies from requiring prior authorization or step therapy for PrEP and PEP. 
This bill primarily affects outpatient prescription drug coverage, which is covered by most health insurance 
coverage as quantified in CHBRP’s Estimates of Pharmacy Benefit Coverage for 2020.   
Due to the amendments made on April 11, 2019, the impacts due to SB 159 would be substantially 
different from those presented here. Because pharmacist would be able to independently furnish only the 
first 30-days of a PrEP regimen, the costs associated with these services would be lower than included 
below. Additionally, utilization changes may be different than presented below. However, the impacts of 
independent furnishing of PEP by pharmacist would be similar. CHBRP is conducting further analysis of 
the impacts of the April 11th amendments.  
This section reports the potential incremental impacts of SB 159, as amended on April 1st, on estimated 
baseline benefit coverage, utilization, and overall cost.  
Key assumptions: 
• CHBRP assumes Truvada®, which is used for prevention of HIV/AIDS in PrEP and PEP, will 
continue to remain as the only single tablet preventive HIV/AIDS medication on the market in 
2020 for the analysis of cost impact.  
• CHBRP assumes a 2% increase in members utilizing Truvada due to the increase for access for 
Truvada through a pharmacist. This assumption was developed with input from CHBRP’s content 
expert. Barriers such as lack of knowledge about PrEP, lack of reimbursement from commercial 
carriers for associated services and slow implementation of necessary processes within 
pharmacies may inhibit adoption by pharmacists, especially in the first year postmandate. 
Additionally, prescriptions obtained directly from pharmacists, such as oral contraceptives, 
experienced slow uptake when first implemented. 
• As discussed in the Policy Context section, medications to prevent HIV are carved out of Medi-
Cal Managed Care plans are provided through the fee-for-service (FFS) program. Therefore, the 
premiums paid for Medi-Cal Managed Care plans will not be impacted by this bill. CHBRP has 
provided estimates of the impact to the FFS program, where able.  
For further details on the underlying data sources and methods used in this analysis, please see 
Appendix C. 
Baseline and Postmandate Benefit Coverage 
Currently, there are 24,490,000 enrollees with health insurance subject to state-level benefit mandates 
and 24,490,000 of these enrollees (or 100%) have health insurance subject to SB 159. Approximately 
0.9% of enrollees in DMHC-regulated plans and CDI-regulated policies have no coverage for outpatient 
prescription drugs (OPDs) and 3.4% have OPD coverage that is not regulated by DMHC or CDI. Such 
health insurance is considered to be compliant with SB159, and so no mandate-related change in benefit 
coverage or utilization would be expected for these enrollees.  
Analysis of California Senate Bill 159 
Current as of April 19, 2019 www.chbrp.org 28 
Additionally, 1.6 million enrollees in the County Organized Health Systems (COHS) and 1.4 million 
persons receiving benefits through the Medi-Cal FFS program would also be impacted by SB 159. 
Current benefit coverage of the provisions in SB 159 was determined by a survey of the largest (by 
enrollment) providers of health insurance in California. Responses to this CHBRP survey represent 74% 
of enrollees with commercial and CalPERS health insurance that can be subject to state mandates. Below 
is a summary of the findings related to baseline benefit coverage and projected postmandate benefit 
coverage.  
CHBRP found 100% of enrollees subject to SB 159 have health insurance that is fully compliant with the 
provision of SB 159 that prohibits prior authorization and step therapy for PrEP and PEP. Thus, there is 
no change in the benefit coverage postmandate for this provision. While some carriers do have prior 
authorization requirements for PrEP, they also have established procedures for bypassing these 
requirements for the initial 30-day supply. Therefore, CHBRP has considered these plans to be in 
compliance with SB 159. 
Pharmacists are not currently able to independently furnish PrEP and PEP. Benefit coverage for this 
provision of SB 159 would increase from 0% at baseline to 100% postmandate (see Table 1). However, 
some pharmacists working in a collaborative practice agreement (CPA) are currently able to furnish PrEP 
and PEP independently to enrollees under the terms of the CPA. 
Baseline and Postmandate Utilization 
MarketScan and Milliman’s proprietary 2016 Consolidated Health Cost Guidelines Sources Database 
(CHSD) which contain Commercial claims, encounters, and enrollment data for the state of California 
were used to quantify the number of enrollees using PrEP and PEP. At baseline, it is estimated there are 
29,395 users of PrEP and 6,055 users of PEP with commercial and CalPERS coverage. Post mandate, 
CHBRP assumes the projected utilization will increase by 2% due to increased access to PrEP and PEP 
directly from a pharmacist. Postmandate, it is estimated there would be 29,982 users of PrEP and 6,176 
users of PEP. 
Provision of PrEP and PEP are “carved out” of Medi-Cal Managed Care plans and COHS and are instead 
provided through the fee-for-service program. There are approximately 10,545,000 enrollees in full-scope 
Medi-Cal in 2020. Although not shown in Table 1, CHBRP estimates that utilization of PrEP will increase 
from 9,000 baseline to 9,180 postmandate (2% utilization increase). The increase in utilization is 
estimated to increase state Medi-Cal expenditures by $1,257,000.  
CHBRP is unable to estimate utilization changes of PEP within Medi-Cal due to lack of data.  
Please refer to Appendix C for details on the methodology used to obtain utilization estimates.  
Baseline and Postmandate Per-Unit Cost  
Baseline costs per annual PrEP and PEP drug regimen of $13,822 were estimated using MarketScan and 
CHSD claims and enrollment data for California in 2016 trended to 2020 (see Table 1). Postmandate, 
CHBRP estimates that this per unit cost will remain constant as the projected increase in utilization 
should not cause the per unit cost to change. Baseline costs for associated HIV and laboratory tests were 
estimated to be $139 annually for PrEP and $157 annually for PEP. CHBRP assumed the Medi-Cal per-
unit cost for both prescription drugs and laboratory tests is 50% of the commercial per-unit cost. 
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Table 4 and Table 5 present baseline and postmandate expenditures by market segment for DMHC-
regulated plans and CDI-regulated policies. The tables present per member per month (PMPM) 
premiums, enrollee expenses for both covered and noncovered benefits, and total expenditures 
(premiums as well as enrollee expenses). 
SB 159 would increase total net annual expenditures by $11,802,000 or 0.0074% for enrollees with 
DMHC-regulated plans and CDI-regulated policies. This is due to a $11,328,000 increase in total health 
insurance premiums paid by employers and enrollees due to an increase in utilization of PrEP and PEP, 
adjusted by an increase in enrollee expenses for covered and/or noncovered benefits. 
The increase in net annual expenditures includes costs associated with increased utilization for both 
PrEP and PEP, including cost of the medications and lab tests. It is unclear whether commercial and 
CalPERS health insurance plans and policies would reimburse pharmacists for the cost of the lab tests 
performed by the pharmacist, or if the pharmacist or enrollee would bear these costs. The increase in 
total net annual expenditures associated with lab tests is $101,000.  
CHBRP estimates total Medi-Cal expenditures would increase by $1,257,000. 
Premiums 
Changes in premiums as a result of SB 159 would vary by market segment. Note that such changes are 
related to the number of enrollees (see Table 1, Table 4, and Table 5), with health insurance that would 
be subject to SB 159.  Increases in private insurance premiums range from a high of $0.0620 PMPM 
among DMHC and CDI-regulated small group plans to a low of $0.0022 PMPM among CDI-regulated 
large group policies. 
Among publicly funded DMHC-regulated health plans, CHBRP estimates no change in DMHC-regulated 
Medi-Cal Managed Care premiums since PrEP and PEP are paid for by FFS Medi-Cal. CalPERS 
premiums are estimated to increase by $0.0473 PMPM.   
Enrollee Expenses 
SB 159-related changes in enrollee expenses for covered benefits (deductibles, copays, etc.) and 
enrollee expenses for noncovered benefits would vary by market segment. Note that such changes are 
related to the number of enrollees (see Table 1, Table 4, and Table 5) with health insurance that would be 
subject to SB 159 and would be expected to use PrEP and PEP and associated lab tests within the first 
year postmandate. 
CHBRP projects no change to copayments or coinsurance rates but does project an increase in utilization 
of PrEP and PEP as well as associated tests and therefore an increase in enrollee cost sharing. Enrollee 
expenses for covered benefits are expected to increase between $0.0020 for enrollees in CalPERS 
HMOs and $0.0025 for enrollees in small group DMHC-regulated plans and CDI-regulated policies, as 
well individual market DMHC-regulated plans. However, should the draft 2019 USPSTF 
recommendations become final, health plans would be required to eliminate cost sharing for PrEP, 
although there may be cost sharing for required lab tests. 
Medi-Cal enrollees do not have cost sharing and therefore would not see an increase in cost sharing.  
CHBRP found that among enrollees with a copayment, about 80% of enrollees had copayments for 
Truvada that were less than or equal to $50 per prescription; among enrollees with a coinsurance, about 
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96% had co-insurance of less than $100 per prescription. Additionally, approximately 8% of claims 
include those where there is $0 (no) copayment or co-insurance for Truvada prescription.  
Out-of-Pocket Spending for Covered and Noncovered Expenses 
When possible, CHBRP estimates the marginal impact of the bill on out-of-pocket spending for covered 
and noncovered expenses, defined as uncovered medical expenses paid by the enrollee as well as out-
of-pocket expenses (e.g., deductibles, copayments, and coinsurance). CHBRP estimates that enrollees 
do not currently pay out-of-pocket for noncovered PrEP or PEP due to existing benefit coverage. Total 
out-of-pocket expenses for enrollees noncovered expenses will not change due to SB 159. 
Potential Cost Offsets or Savings in the First 12 Months After Enactment 
CHBRP does not project any cost offsets or savings in health care that would result because of the 
enactment of provisions in SB 159. While the increase in utilization of PrEP and PEP in the first year 
postmandate may reduce the number of new HIV cases in California, the short-term impacts are likely to 
be negligible. However, should the increase utilization of PrEP and PEP result in avoided HIV 
transmission, the costs associated with HIV positive enrollees would decrease and offset some or all of 
the increased cost associated with PrEP and PEP. 
Postmandate Administrative Expenses and Other Expenses 
CHBRP estimates that the increase in administrative costs of DMHC-regulated plans and/or CDI-
regulated policies will remain proportional to the increase in premiums. CHBRP assumes that if health 
care costs increase as a result of increased utilization or changes in unit costs, there is a corresponding 
proportional increase in administrative costs. CHBRP assumes that the administrative cost portion of 
premiums is unchanged. All health plans and insurers include a component for administration and profit in 
their premiums. 
Other Considerations for Policymakers 
In addition to the impacts a bill may have on benefit coverage, utilization, and cost, related considerations 
for policymakers are discussed below. 
Postmandate Changes in the Number of Uninsured Persons35 
Because the change in average premiums does not exceed 1% for any market segment (see Table 1, 
Table 4, and Table 5), CHBRP would expect no measurable change in the number of uninsured persons 
due to the enactment of SB 159. 
Changes in Public Program Enrollment 
CHBRP estimates that the mandate would produce no measurable impact on enrollment in publicly 
funded insurance programs due to the enactment of SB 159. 
                                                     
35 See also CHBRP’s Uninsured: Criteria and Methods for Estimating the Impact of Mandates on the Number of 
Individuals Who Become Uninsured in Response to Premium Increases (December 2015), available at 
http://chbrp.com/analysis_methodology/cost_impact_analysis.php.  
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How Lack of Benefit Coverage Results in Cost Shifts to Other Payers 
CHBRP estimates no measureable cost shifting to other payers since all enrollees have currently have 
coverage for PrEP and PEP. 
However, for enrollees for whom cost sharing is burdensome, some external assistance may be available. 
Patient assistance programs offer copayment relief for private insurance enrollees if they meet certain 
financial requirements (Smith et al., 2017). Gilead Sciences Inc., manufacturer of Truvada, offers a 
patient assistance program that assists with patient co-payment expenses (Truvada for PrEP Medication 
Assistance Program). After the co-payment assistance threshold of $7,200 per calendar year is met, the 
California Department of Public Health’s PrEP Assistance Program provides wrap around coverage for 
any remaining PrEP medication copayments for the remainder of the calendar year.36 CHBRP does not 
have access to any data to quantify the impact of financial support and patient assistance programs and 
how they impact enrollee expenses.   
                                                     
36 California Department of Public Health. Office of AIDS. PrEP-AP Program. Available at: 
https://www.cdph.ca.gov/Programs/CID/DOA/Pages/OA_adap_benefits_prepAP.aspx. Accessed on April 17, 2019.  
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Table 4. Baseline Per Member Per Month Premiums and Total Expenditures by Market Segment, California, 2020 
  DMHC-Regulated  CDI-Regulated   
  Privately Funded Plans 
(by Market) (a) 
 Publicly Funded Plans  Privately Funded Plans 
(by Market) (a) 
  
  Large 
Group 
Small 
Group 
Individual  CalPERS 
HMOs (b) 
MCMC 
(Under 65) 
(c) 
MCMC 
(65+) (c) 
 Large 
Group 
Small 
Group 
Individual  Total 
Enrollee counts              
 
Total enrollees in 
plans/policies 
subject to state 
mandates (d) 10,565,000 3,099,000 2,184,000 
 
523,000 6,796,000 795,000 
 
318,000 108,000 102,000 
 
24,490,000 
 
Total enrollees in 
plans/policies 
subject to SB 159 10,565,000 3,099,000 2,184,000 
 
523,000 6,796,000 795,000 
 
318,000 108,000 102,000 
 
24,490,000 
Premiums                       
 
Average portion 
of premium paid 
by employer $555.35 $341.99 $0.00  $493.71 $268.13 $694.55  $710.92 $462.84 $0.00  $118,029,198,000 
 
Average portion 
of premium paid 
by employee $39.66 $205.44 $437.39  $94.04 $0.00 $0.00  $250.37 $202.64 $475.67  $26,521,718,000 
 Total premium $595.01 $547.43 $437.39  $587.76 $268.13 $694.55  $961.29 $665.48 $475.67  $144,550,916,000 
Enrollee expenses                       
 
For covered 
benefits 
(deductibles, 
copays, etc.) $46.18 $121.03 $115.38  $48.33 $0.00 $0.00  $162.44 $186.84 $168.51  $14,750,880,000 
 
For noncovered 
benefits (e) $0.00 $0.00 $0.00  $0.00 $0.00 $0.00  $0.00 $0.00 $0.00  $0 
 
Total 
expenditures $641.19 $668.46 $552.77  $636.08 $268.13 $694.55  $1,123.73 $852.31 $644.18  
$159,301,796,000 
Source: California Health Benefits Review Program, 2019. 
Notes: (a) Includes enrollees with grandfathered and nongrandfathered health insurance acquired outside or through Covered California (the state’s health insurance marketplace). 
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(b) Approximately 56.17% of CalPERS enrollees in DMHC-regulated plans are state retirees, state employees, or their dependents. About one in five (20.5%) of these enrollees has a 
pharmacy benefit not subject to DMHC.37  CHBRP has projected no impact for those enrollees.  However, CalPERS could, postmandate, require equivalent coverage for all its 
members (which could increase the total impact on CalPERS).  
(c) Medi-Cal Managed Care Plan expenditures for members over 65 include those who are also Medicare beneficiaries. This population does not include enrollees in COHS. 
(d) Enrollees in plans and policies regulated by DMHC or CDI aged 0 to 64 years as well as enrollees 65 years or older in employer-sponsored health insurance. This group includes 
commercial enrollees (including those associated with Covered California or CalPERS) and Medi-Cal beneficiaries enrolled in DMHC-regulated plans.38  
(e) Includes only those expenses that are paid directly by enrollees or other sources to providers for services related to the mandated benefit that are not currently covered by 
insurance. This only includes those expenses that will be newly covered, postmandate. Other components of expenditures in this table include all health care services covered by 
insurance. 
Key: CalPERS HMOs = California Public Employees’ Retirement System Health Maintenance Organizations; CDI = California Department of Insurance; COHS = County Organized 
Health Systems; DMHC = Department of Managed Health Care; MCMC = Medi-Cal Managed Care. 
 
                                                     
37 For more detail, see Estimates of Pharmacy Benefit Coverage, available at  http://chbrp.com/analysis_methodology/cost_impact_analysis.php).   
38 For more detail, see Estimates of Sources of Health Insurance in California, available at  http://chbrp.com/analysis_methodology/cost_impact_analysis.php.   
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Table 5. Postmandate Per Member Per Month Premiums and Total Expenditures by Market Segment, California, 2020 
  DMHC-Regulated  CDI-Regulated   
  Privately Funded Plans 
(by Market) (a) 
 Publicly Funded Plans  Privately Funded Plans 
(by Market) (a) 
  
  Large 
Group 
Small 
Group 
Individual  CalPERS 
HMOs (b) 
MCMC 
(Under  
65) (c) 
MCMC 
(65+) (c) 
 Large 
Group 
Small 
Group 
Individual  Total 
Enrollee counts              
 
Total enrollees in 
plans/policies 
subject to state 
mandates (d) 10,565,000 3,099,000 2,184,000 
 
523,000 6,796,000 795,000 
 
318,000 108,000 102,000 
 
24,490,000 
 
Total enrollees in 
plans/policies 
subject to SB 159 10,565,000 3,099,000 2,184,000 
 
523,000 6,796,000 795,000 
 
318,000 108,000 102,000 
 
24,490,000 
Premiums                       
 
Average portion of 
premium paid by 
employer $0.0497 $0.0387 $0.0000  $0.0397 $0.0000 $0.0000  $0.0383 $0.0431 $0.0000  $8,198,000 
 
Average portion of 
premium paid by 
employee $0.0036 $0.0233 $0.0619  $0.0076 $0.0000 $0.0000  $0.0135 $0.0189 $0.0563  $3,130,000 
 Total premium $0.0533 $0.0620 $0.0619  $0.0473 $0.0000 $0.0000  $0.0519 $0.0620 $0.0563  $11,328,000 
Enrollee expenses                       
 
For covered 
benefits 
(deductibles, 
copays, etc.) $0.0023 $0.0025 $0.0025  $0.0020 $0.0000 $0.0000  $0.0022 $0.0025 $0.0023  $474,000 
 
For noncovered 
benefits (e) $0.0000 $0.0000 $0.0000  $0.0000 $0.0000 $0.0000  $0.0000 $0.0000 $0.0000  $0 
 
Total 
expenditures $0.0556 $0.0645 $0.0644  $0.0493 $0.0000 $0.0000  $0.0541 $0.0645 $0.0586  $11,802,000 
Percent change                    
 Premiums 0.0090% 0.0113% 0.0142%  0.0080% 0.0000% 0.0000%  0.0054% 0.0093% 0.0118%  0.0078% 
 
Total 
expenditures 0.0087% 0.0096% 0.0117%  0.0078% 0.0000% 0.0000%  0.0048% 0.0076% 0.0091%  0.0074% 
Source: California Health Benefits Review Program, 2019. 
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Notes: (a) Includes enrollees with grandfathered and nongrandfathered health insurance acquired outside or through Covered California (the state’s health insurance marketplace). 
(b) Approximately 56.17% of CalPERS enrollees in DMHC-regulated plans are state retirees, state employees, or their dependents. About one in five (20.5%) of these enrollees has a pharmacy 
benefit not subject to DMHC.39  CHBRP has projected no impact for those enrollees.  However, CalPERS could, postmandate, require equivalent coverage for all its members (which could 
increase the total impact on CalPERS).  
(c) Medi-Cal Managed Care Plan expenditures for members over 65 include those who are also Medicare beneficiaries. This population does not include enrollees in COHS. 
(d) Enrollees in plans and policies regulated by DMHC or CDI aged 0 to 64 years as well as enrollees 65 years or older in employer-sponsored health insurance.  This group includes commercial 
enrollees (including those associated with Covered California or CalPERS) and Medi-Cal beneficiaries enrolled in DMHC-regulated plans.40  
(e) Includes only those expenses that are paid directly by enrollees or other sources to providers for services related to the mandated benefit that are not currently covered by insurance. This 
only includes those expenses that will be newly covered, postmandate. Other components of expenditures in this table include all health care services covered by insurance. 
Key: CalPERS HMOs = California Public Employees’ Retirement System Health Maintenance Organizations; CDI = California Department of Insurance; COHS = County Organized Health 
Systems; DMHC = Department of Managed Health Care; MCMC = Medi-Cal Managed Care. 
                                                     
39 For more detail, see Estimates of Pharmacy Benefit Coverage, available at  http://chbrp.com/analysis_methodology/cost_impact_analysis.php).   
40 For more detail, see Estimates of Sources of Health Insurance in California, available at  http://chbrp.com/analysis_methodology/cost_impact_analysis.php.   
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PUBLIC HEALTH IMPACTS 
As discussed in the Policy Context section, SB 159 as amended April 1st would authorize pharmacists to 
initiate and furnish pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP) for HIV/AIDS, 
prohibit commercial insurance plans from subjecting coverage of PrEP and PEP to prior authorization and 
step therapy, and expand the Medi-Cal schedule of benefits to include coverage and payment for PrEP 
and PEP provided by pharmacists.  
The public health impact analysis includes estimated impacts in the short term (within 12 months of 
implementation) and in the long term (beyond the first 12 months postmandate). This section estimates 
the short-term impact41 of SB 159 as amended on April 1st on utilization of PrEP and PEP, HIV incidence, 
HIV risk reduction, HIV transmission, quality of life, racial and ethnic disparities, and financial burden. See 
Long-Term Impacts for discussion of social determinants of health. 
The public health impacts of SB 159 as amended on April 11th would be different than those presented 
below. While the Medical Effectiveness review would remain relevant, the differences in the cost impact 
analysis, as discussed above, would alter the public health impacts. 
Estimated Public Health Outcomes 
Measurable health outcomes relevant to SB 159 include HIV transmission, adherence to PrEP and PEP 
regimens, HIV incidence, HIV risk reduction, and quality of life. 
As presented in the Medical Effectiveness section: 
• There is clear and convincing evidence PrEP is effective in preventing HIV transmission and 
lowering the risk of HIV among high-risk groups with moderate or high adherence. 
• There is limited evidence that PEP is effective in preventing HIV transmission following 
occupational and nonoccupational exposures.  
• There is insufficient evidence to assess the impact of prohibiting prior authorization or step 
therapy on prescription of and adherence to PrEP or PEP.  
• There is insufficient evidence to assess the ability of pharmacists to safely and effectively 
prescribe PrEP or PEP. 
As presented in Benefit Coverage, Utilization, and Cost Impacts, 100% of enrollees subject to SB 159 
have coverage for PrEP and PEP without prior authorization or step therapy requirements. Therefore, no 
utilization increase would occur due to SB 159 prohibiting these utilization management policies among 
DMHC-regulated plans and CDI-regulated policies. Conversely, pharmacists are not able to 
independently furnish PrEP and PEP at baseline, meaning 0% of enrollees are able to obtain PrEP and 
PEP through a pharmacist without a prescription from another provider. Postmandate, benefit coverage 
will increase to 100%, meaning all enrollees will be able to seek PrEP and PEP directly from a pharmacist 
without needing to obtain a prescription from another provider. Due to this change in benefit coverage, 
utilization of PrEP and PEP will increase by 2%. Utilization of PrEP will increase by 588 enrollees (from 
29,395 at baseline to 29,982 postmandate) in commercial and CalPERS plans and by 180 enrollees (from 
9,000 at baseline to 9,180 postmandate) in Medi-Cal. Utilization of PEP will increase by 121 enrollees 
                                                     
41 CHBRP defines short-term impacts as changes occurring within 12 months of bill implementation. 
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(from 6,055 at baseline to 6,176 postmandate) in commercial and CalPERS plans and by an unknown 
number of enrollees in Medi-Cal.  
Prohibition of Prior Authorization and Step Therapy 
According to CHBRP’s content expert for SB 159, prior authorization requirements can result in a delay of 
obtaining PrEP of 24 to 48 hours. For enrollees seeking PrEP, some enrollees may fail to return to their 
provider or the pharmacy to fill the prescription, resulting in lower utilization of PrEP. As described in the 
Benefit Coverage, Utilization, and Cost Impacts section, 0% of enrollees currently have health insurance 
coverage that places prior authorization or step therapy requirements on the provision of PrEP or PEP. 
While some carriers indicated they do have formal prior authorization requirements in place, they stated 
they also authorize an immediate 30-day supply of Truvada while enrollees work with their providers to 
meet the prior authorization requirements or indicated the prior authorization requirements are being 
phased out.  
Carriers indicated they did not place prior authorization requirements on the provision of PEP.  
As stated in the Medical Effectiveness section, there is insufficient evidence to determine if prohibiting 
prior authorization for the provision of PrEP and PEP increases the likelihood that health professionals 
with prescribing authority will prescribe PrEP or PEP, improve adherence to PrEP or PEP, or improve 
health outcomes for people taking PrEP or PEP. However, there is limited evidence that prior 
authorization requirements for medications used to treat HIV delay receipt of care.  
CHBRP estimates the provision of SB 159 that prohibits prior authorization and step therapy would 
produce no public health impact because carriers have established procedures for bypassing prior 
authorization requirements. It is possible that enrollees encounter prior authorization requirements and 
are not able to obtain the bypass for immediate authorization for PrEP. Therefore, it is possible the 
prohibition of prior authorization will enable more enrollees to obtain PrEP more quickly.  
Pharmacist Provision of HIV Prophylaxis  
In order for pharmacists to be able to independently furnish PrEP and PEP in California postmandate, 
they must complete an approved education course and provide services to enrollees including testing for 
HIV, counseling and education, and additional laboratory tests. Should the education course be available 
immediately after SB 159 is signed into law, it will still take time for pharmacists to take the course and 
adapt their pharmacy practice to be able to furnish PrEP and PEP and provide the associated services. 
While pharmacists are able to bill Medi-Cal for the associated services (e.g. lab tests and patient 
counseling), there is currently no mechanism in place for pharmacists to bill commercial health plans for 
associated services, unless the pharmacist practices within a closed system, such as Kaiser Permanente.  
It stands to reason that pharmacists in California would be willing to furnish PrEP, with additional training. 
However, as discussed in the Background section, barriers such as lack of knowledge about PrEP, lack 
of reimbursement from commercial carriers for associated services and slow implementation of necessary 
processes within pharmacies may inhibit adoption by pharmacists.  
A 2017 study found that the HIV incidence among MSM who did not use PrEP was 50 per 1,000 and the 
HIV incidence among MSM who did use PrEP was 17 per 1,000, an absolute difference of 33 cases of 
HIV per 1,000 men (Allende and Acuna, 2017). While CHBRP is unable to discern the characteristics of 
new PrEP users due to the implementation of SB 159, assuming utilization and adherence of PrEP for all 
populations is similar to the utilization and adherence of the MSM population would be a best case 
scenario. If none of the estimated 768 new users of PrEP do not use PrEP, the findings of the 2017 study 
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suggest that 38 will seroconvert and become HIV positive. If the estimated 768 new users do use PrEP, 
the study findings suggest that 13 will seroconvert and become HIV positive, resulting in a reduction of 25 
new cases of HIV, assuming that utilization and adherence among all new PrEP users is similar to that of 
MSM.    
In the first year postmandate, CHBRP estimates 768 additional enrollees will obtain PrEP through 
pharmacists, which would result in a reduction of 25 new HIV cases. For the 121 additional enrollees who 
will obtain PEP through pharmacists, a small reduction in the number of new HIV cases would be 
expected as well. This estimate is supported by limited evidence that pharmacists are able to safely and 
effectively prescribe PrEP and provide related services and that the availability of these services from 
pharmacists will result in an increase in utilization (2%) of PrEP and PEP. The increase in utilization is 
dampened by limited adoption of the requirements to independently furnish PrEP and PEP by 
pharmacists and pharmacies within the first year postmandate.  
Utilization of PrEP  
As discussed in the Background section, between 221,528 and 238,628 Californians would meet the 
criteria for PrEP, which is about double the prevalence of people living with HIV in California in 2016. 
Populations at high risk for contracting HIV include men who have sex with men (MSM), transgender 
women, African Americans, Latinos and persons who inject drugs.  
The use of PrEP may vary according to individual characteristics. Morgan et al. (2018), a longitudinal 
cohort study conducted in the United States, found that those who reported more sex partners (AOR = 
1.07, 95% CI = 1.03–1.12) and older individuals (AOR=1.18, 95% CI=1.07-1.30) were significantly more 
likely to have used PrEP in the past 6 months, whereas those with potentially hazardous marijuana use 
were significantly less likely to use have used PrEP in the past 6 months (AOR = 0.94, 95% CI = 0.89–
0.99). No significant differences were found for race/ethnicity, education, other drug use, nor alcohol use.  
Approximately 38,295 enrollees subject to SB 159 use PrEP premandate, far below the population that 
meets criteria for PrEP. Although enabling pharmacists to independently furnish PrEP would increase 
utilization by 2% in the first year postmandate, utilization could continue to increase as more pharmacists 
take the required training. However, barriers such as lack of reimbursement for associated services such 
as patient counseling and lab tests could limit future utilization increases. 
Potential Harms From SB 159 
When data are available, CHBRP estimates the marginal change in relevant harms associated with 
interventions affected by the proposed mandate.  
As discussed in the Medical Effectiveness section, in the case of SB 159, there is inconclusive evidence 
to suggest that an increase in the use of PrEP could result in harm. There is inconclusive evidence that 
condom use is lower among users of PrEP and that incidence of STIs are higher among users of PrEP. 
While some users may experience harms in the form of higher rates of STIs, rates of STIs overall are 
higher among the population targeted for PrEP use. Users of PrEP do not experience higher rates of 
adverse events from the medications, higher rates of antiretroviral drug resistance, or poorer reproductive 
outcomes compared to non-users. There is a preponderance of evidence that PrEP uptake does not lead 
to a difference in the number of sexual partners. 
However, potential harms associated with the use of PEP include adverse events resulting from 
medication toxicities. The currently recommended regimen for PEP has the lowest observed 
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discontinuation rate due to adverse events. Reactions to the medications include side effects consisting 
of nausea/vomiting, diarrhea, headache, and fatigue. Despite the possible side effects, limited evidence 
shows that the benefits of taking PEP to avoid developing HIV post-exposure outweigh the harms. 
Impact on Disparities42 
Insurance benefit mandates that bring more state-regulated plans and policies to parity may change an 
existing disparity. As described in the Background section, disparities in utilization exist by race and 
ethnicity, and gender identity and sexual orientation. Although the impact of SB 159 on disparities is 
unknown due to lack of data, it possible that within the first 12 months postmandate, SB 159 could reduce 
some disparities in utilization of PrEP. (For discussion of potential impacts beyond the first 12 months of 
implementation [including SDoH], see Long-Term Impacts.) 
CHBRP is unable to estimate short-term impacts of SB 159 on the impact of disparities for utilization of 
PEP due to lack of data.  
Impact on Racial or Ethnic Disparities 
As discussed in the Background section, although blacks and Hispanics in California are at highest risk of 
contracting HIV, utilization of PrEP is highest among white Californians. Although SB 159 may somewhat 
expand access to PrEP for enrollees by enabling them to access medications directly through a 
pharmacist, the impact of SB 159 is unknown.  
It is possible SB 159 could reduce racial and ethnic disparities for high risk populations who do not have a 
usual source of care or are uncomfortable asking their usual source of care for a PrEP prescription. 
However, the impact of SB 159 on reducing documented disparities among racial and ethnic groups (see 
the Background section) is unknown because data are unavailable to estimate changes in the utilization 
of PrEP among enrollees by race or ethnicity.  
Impact on Sexual Orientation and Gender Identity Disparities 
As discussed in the Background section, MSM and transgender women are at highest risk for contracting 
HIV, but have among the lowest initiation and continuation rates of PrEP. PrEP is most effective when 
adherence to the regimen is high. Expanding access to PrEP through pharmacists could increase 
initiation and adherence due to MSM and transgender women seeking more anonymous care or choosing 
to go to an alternate provider.  
The extent to which sexual orientation and gender identity disparities may be impacted by SB 159 is 
unknown because data are unavailable to estimate changes in the utilization of PrEP among these 
enrollees.  
 
  
                                                     
42. For details about CHBRP’s methodological approach to analyzing disparities, see the Benefit Mandate Structure 
and Unequal Racial/Ethnic Health Impacts document here: 
http://chbrp.com/analysis_methodology/public_health_impact_analysis.php. 
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LONG-TERM IMPACTS 
In this section, CHBRP estimates the long-term impact43 of SB 159 as amended on April 1st, which 
CHBRP defines as impacts occurring beyond the first 12 months after implementation. These estimates 
are qualitative and based on the existing evidence available in the literature. CHBRP does not provide 
quantitative estimates of long-term impacts because of unknown improvements in clinical care, changes 
in prices, implementation of other complementary or conflicting policies, and other unexpected factors. 
Amendments made to SB 159 on April 11th would alter the below impacts.  
Long-Term Utilization and Cost Impacts 
Utilization Impacts  
After the increase in utilization in the first 12 months, CHBRP estimates the utilization will increase 
gradually before leveling off. CHBRP assumes the gradual increase will be due to increased awareness 
of PrEP and PEP among enrollees and increased preparedness by pharmacists and pharmacies.  
However, after several years, CHBRP expects the utilization to level off because the rate of enrollees 
using PrEP and PEP will also remain generally consistent over time. 
Cost Impacts 
Over the long term, CHBRP assumes as utilization continues to increase, corresponding costs will also 
increase. CHBRP also assume that as utilization for PrEP and PEP increases, potentially fewer enrollees 
will contract HIV. Thus, the costs associated with HIV-positive enrollees would decrease and offset some 
or all of the increased cost associated with PrEP and PEP. 
Long-Term Public Health Impacts 
Some interventions in proposed mandates provide immediate measurable impacts (e.g., maternity service 
coverage or acute care treatments), whereas other interventions may take years to make a measurable 
impact (e.g., coverage for tobacco cessation or vaccinations). When possible, CHBRP estimates the long-
term effects (beyond 12-months postmandate) to the public’s health that would be attributable to the 
mandate, including impacts on social determinants of health, premature death, and economic loss.  
In the case of SB 159, CHBRP estimates utilization of PrEP and PEP will continue to increase as 
pharmacists obtain the required training and awareness of PrEP and PEP increases, eventually leveling 
out; therefore, the number of enrollees who will avoid contracting HIV will increase over time.. 
Impacts on Disparities and the Social Determinants of Health44  
In the case of SB 159, evidence shows that access to PrEP may be lower in rural areas compared to 
urban areas and perceived stigma from providers is a substantial barrier for PrEP-eligible patients. 
                                                     
43 See also CHBRP’s Criteria and Guidelines for the Analysis of Long-Term Impacts on Healthcare Costs and Public 
Health, available at http://www.chbrp.org/analysis_methodology/cost_impact_analysis.php.  
44 For more information about SDoH, see CHBRP’s publication Incorporating Relevant Social Determinants of Health 
into CHBRP Benefit Mandate Analyses at 
http://chbrp.com/analysis_methodology/public_health_impact_analysis.php.  
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Additionally, disparities in utilization of PrEP exist between racial and ethnic groups and by gender 
identity and sexual orientation.  
Periodically, health insurance mandates can influence SDoH, which can mediate health inequities. 
Evidence presented in the Background section indicates that geography and provider stigma are 
associated with lower utilization of PrEP. Enabling pharmacists to independently furnish PrEP may 
improve access for enrollees in rural areas due to increased availability. Additionally, if an enrollee 
perceives judgement from their primary care provider, they would be able to turn to a pharmacist for care. 
Although the pharmacist would need to record the provision of PrEP in the enrollee’s record, the enrollee 
must consent for the pharmacist to notify the enrollee’s primary care provider.  
Should utilization of PrEP continue to increase, CHBRP estimates that SB 159 could alter geographic and 
stigma related disparities by improving access to PrEP through alternate locations.  
However, other factors unrelated to insurance coverage of PrEP may limit utilization by PrEP-targeted 
populations. Awareness and knowledge of PrEP remain lowest among MSM and transgender women, as 
well as among blacks and Hispanics, the groups that have the highest risk of contracting HIV. In order for 
independent furnishing of PrEP by pharmacists to increase utilization, patients need to be engaged in HIV 
prevention and seek PrEP from pharmacists.   
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APPENDIX A  TEXT OF BILL ANALYZED 
On February 28, 2019, the California Senate Committee on Health requested that CHBRP analyze SB 
159. 
SB 159 was introduced on January 23, 2019, amended on February 27, 2019 and amended on April 1, 
2019. CHBRP, with agreement from the requesting Health Committee, has analyzed the text as it was 
amended on April 1, 2019. 
 
 
SENATE BILL  No. 159 
 
 
Introduced by Senator Wiener 
(Principal coauthors: Assembly Members Gipson and Gloria) 
(Coauthor: Assembly Member Chiu) 
 
January 23, 2019 
Amended in Senate February 27, 2019 
Amended in Senate April 1, 2019 
 
 
An act to add Section 4052.02 to the Business and Professions Code, to add Section 1342.74 to 
the Health and Safety Code, to add Section 10123.1933 to the Insurance Code, and to amend 
Section 14132.968 of the Welfare and Institutions Code, relating to HIV prevention.  
 
LEGISLATIVE COUNSEL'S DIGEST 
 
SB 159, as amended, Wiener. HIV: preexposure and postexposure prophylaxis. 
 
Existing law, the Pharmacy Law, provides for the licensure and regulation of pharmacists by the 
California State Board of Pharmacy, and makes a violation of these requirements a crime. 
Existing law generally authorizes a pharmacist to dispense or furnish drugs only pursuant to a 
valid prescription, except as provided, such as furnishing emergency contraceptives, hormonal 
contraceptives, and naloxone hydrochloride, pursuant to standardized procedures. 
 
This bill would authorize a pharmacist to initiate and furnish preexposure prophylaxis and 
postexposure prophylaxis if a prophylaxis, in specified amounts, if the pharmacist completes a 
training program approved by the board, board and complies with specified requirements, such 
as assessing a patient and providing a patient with counseling and tests, and provides these if 
those services can be provided in a private and sanitary location. Because a violation of these 
requirements would be a crime, this bill would impose a state-mandated local program. 
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Existing law provides for the Medi-Cal program, which is administered by the State Department 
of Health Care Services, under which qualified low-income individuals receive health care 
services pursuant to a schedule of benefits, including pharmacist services, which are subject to 
approval by the federal Centers for Medicare and Medicaid Services. The Medi-Cal program is, 
in part, governed and funded by federal Medicaid program provisions. 
 
This bill would expand the Medi-Cal schedule of benefits to include preexposure prophylaxis 
and postexposure prophylaxis as pharmacist services. 
 
Existing law, the Knox-Keene Health Care Service Plan Act of 1975, provides for the licensure 
and regulation of health care service plans by the Department of Managed Health Care and 
makes a willful violation of the act a crime. Existing law also provides for the regulation of 
health insurers by the Department of Insurance. Existing law authorizes health care service plans 
and health insurers that cover prescription drugs to utilize reasonable medical management 
practices, including prior authorization and step therapy, consistent with applicable law. For 
combination antiretroviral drug treatments medically necessary for the prevention of AIDS/HIV, 
existing law prohibits plans and insurers, until January 1, 2023, from having utilization 
management policies or procedures that rely on a multitablet drug regimen instead of a single-
tablet drug regimen, except as specified. 
 
This bill would additionally prohibit plans and insurers from subjecting those drug treatments, 
including preexposure prophylaxis or postexposure prophylaxis, to prior authorization or step 
therapy. Because a willful violation of these provisions would be a crime, this bill would impose 
a state-mandated local program. 
 
The California Constitution requires the state to reimburse local agencies and school districts for 
certain costs mandated by the state. Statutory provisions establish procedures for making that 
reimbursement. 
 
This bill would provide that no reimbursement is required by this act for a specified reason. 
 
Digest Key 
 
Vote: MAJORITY   Appropriation: NO   Fiscal Committee: YES   Local Program: YES   
 
 
BILL TEXT 
 
THE PEOPLE OF THE STATE OF CALIFORNIA DO ENACT AS FOLLOWS: 
 
SECTION 1. 
Section 4052.02 is added to the Business and Professions Code, to read: 
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4052.02. (a) Notwithstanding any other law, a pharmacist may initiate and furnish prexposure 
HIV preexposure prophylaxis and postexposure prophylaxis in accordance with this section. 
 
(b) Before furnishing preexposure prophylaxis or postexposure prophylaxis to a patient, a 
pharmacist shall complete a training program approved by the board that addresses on the use of 
preexposure prophylaxis and postexposure prophylaxis. The board shall consult with the 
California Pharmacists Association and the Office of AIDS, within the State Department of 
Public Health, on training programs that are appropriate to meet the requirements of this 
subdivision. 
 
(c) A pharmacist may furnish an initial course of preexposure prophylaxis as determined by the 
federal Centers for Disease Control and Prevention guidelines if the pharmacist completes all of 
the following: 
 
(1) Screens the patient for human immunodeficiency virus (HIV) and Provides HIV testing and 
confirms a negative test result or determines that the patient has recently received a negative 
HIV test within the last seven days. result consistent with the most recent guidelines from the 
federal Centers for Disease Control and Prevention. If the patient tests positive for HIV 
infection, the pharmacist or person administering the test shall inform the patient that there are 
numerous treatment options available and identify followup testing and care that may be 
recommended, including contact information for medical and psychological services. 
 
(2) Provides counseling to the patient, including a side effect assessment, patient on the ongoing 
use of preexposure prophylaxis consistent with the most recent guidelines from the federal 
Centers for Disease Control and Prevention, which may include education about side effects of 
the medication effects, safety during pregnancy and breastfeeding, adherence to recommended 
dosing, and the importance of adhering to the drug regimen, timely testing and treatment, as 
applicable, for HIV and sexually transmitted diseases, behavioral risk reduction support, and 
pregnancy testing. HIV, renal function, hepatitis B, hepatitis C, sexually transmitted diseases, 
and pregnancy for individuals of child-bearing capacity. 
(3)Advises the patient on current guidelines and recommendations by the federal Centers for 
Disease Control and Prevention regarding ongoing use of the medication. 
(4) 
(3) Documents the services provided by the pharmacist in the patient’s health record. 
(5) 
(4) Notifies the patient’s primary care provider that the pharmacist completed the requirements 
specified in this subdivision. If the patient does not have a primary care provider, or refuses 
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consent to notify a the patient’s primary care provider, the pharmacist shall provide the patient a 
list of physicians and surgeons, clinics, or other health care service providers to contact for 
health care services. regarding ongoing care for preexposure prophylaxis. 
 
(d) A pharmacist may refill a prescription pursuant to this section if, prior to refilling the 
prescription, the pharmacist completes all of the following: 
 
(1) Ensures the patient is clinically eligible for use of preexposure prophylaxis consistent with 
the most recent guidelines from the federal Centers for Disease Control and Prevention, which 
may include providing or determining the patient has received timely testing and treatment, as 
applicable, for HIV, renal function, hepatitis B, hepatitis C, sexually transmitted diseases, and 
pregnancy for individuals of child-bearing capacity. 
 
(2) Documents the services provided by the pharmacist in the patient’s health record. 
 
(3) Notifies the patient’s primary care provider that the pharmacist completed the requirements 
specified in this subdivision. If the patient does not have a primary care provider, or refuses 
consent to notify the patient’s primary care provider, the pharmacist shall provide the patient a 
list of physicians and surgeons, clinics, or other health care service providers to contact 
regarding ongoing care for preexposure prophylaxis. 
(d) 
(e) A pharmacist may furnish a complete course or 30-day supply of postexposure prophylaxis if 
the pharmacist completes all of the following: 
 
(1) Screens the patient for HIV and determines the exposure meets the clinical criteria for use 
consideration of postexposure prophylaxis consistent with the most recent guidelines from the 
federal Centers for Disease Control and Prevention. 
 
(2) Provides HIV testing or determines the patient is willing to receive an HIV test undergo HIV 
testing consistent with the most recent guidelines from the federal Centers for Disease Control 
and Prevention. 
 
(3) Provides counseling to the patient on the use of the medication postexposure prophylaxis 
consistent with the most recent guidelines from the federal Centers for Disease Control and 
Prevention, including which may include education about side effects of the medication, effects, 
safety during pregnancy and breastfeeding, adherence to recommended dosing, and the 
importance of adhering to the drug regimen and testing timely testing and treatment, as 
applicable, for HIV and sexually transmitted diseases. 
 
(4) Notifies the patient’s primary care provider of the postexposure prophylaxis treatment. If the 
patient does not have a primary care provider, or refuses consent to notify a the patient’s primary 
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care provider, the pharmacist shall provide the patient a list of physicians and surgeons, clinics, 
or other health care service providers to contact for health care services. regarding followup care 
for postexposure prophylaxis. 
(e) 
(f) A pharmacist initiating or furnishing preexposure prophylaxis or postexposure prophylaxis 
shall not permit the person to whom the drug is furnished to waive the consultation required by 
the board and the Medical Board of California. 
(f)A pharmacist who provides 
(g) Notwithstanding any other law, a pharmacist is not required to provide the counseling, 
assessments, or tests, as prescribed in this section, shall ensure that these services are provided in 
a private and sanitary location, without interruption by others, and the pharmacist shall not be 
interrupted tests specified in subdivision (c), (d), or (e) if the pharmacist cannot conduct the 
counseling, assessments, or tests at a location that is sufficiently private to permit the pharmacist 
to comply with the federal Health Insurance Portability and Accountability Act and applicable 
state law governing the privacy of medical information, meets the sanitation standards under 
applicable law governing pharmacy practice, and allows the pharmacist to provide the services 
without being interrupted by others or called away to perform other duties. 
(g) 
(h) The board and the Medical Board of California are each authorized to ensure compliance 
with this section. Each board is specifically charged with enforcing this section with respect to its 
respective licensees. 
(h) 
(i) The board may adopt emergency regulations to establish necessary procedures or protocols. 
These emergency regulations shall be developed in accordance with the most current guidelines 
from the federal Centers for Disease Control and Prevention. The adoption of regulations 
pursuant to this subdivision shall be deemed to be an emergency and necessary for the immediate 
preservation of the public peace, health, safety, or general welfare. The emergency regulations 
authorized by this subdivision are exempt from review by the Office of Administrative Law. The 
emergency regulations authorized by this subdivision shall be submitted to the Office of 
Administrative Law for filing with the Secretary of State and shall remain in effect until the 
earlier of 180 days following their effective date or the effective date of regulations adopted 
pursuant to Section 4005. 
(i) 
(j) This section does not limit a pharmacist’s scope of practice described in Section 4052.2. 
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SEC. 2. 
Section 1342.74 is added to the Health and Safety Code, immediately following Section 1342.73, 
to read: 
 
1342.74. Notwithstanding Section 1342.71, a health care service plan shall not subject 
combination antiretroviral drug treatments that are medically necessary for the prevention of 
AIDS/HIV, including preexposure prophylaxis or postexposure prophylaxis, to prior 
authorization or step therapy. 
SEC. 3. 
Section 10123.1933 is added to the Insurance Code, immediately following Section 10123.1932, 
to read: 
 
10123.1933. Notwithstanding Section 10123.201, a health insurer shall not subject combination 
antiretroviral drug treatments that are medically necessary for the prevention of AIDS/HIV, 
including preexposure prophylaxis or postexposure prophylaxis, to prior authorization or step 
therapy. 
SEC. 4. 
Section 14132.968 of the Welfare and Institutions Code is amended to read: 
14132.968.(a) (1) Pharmacist services are a benefit under the Medi-Cal program, subject to 
approval by the federal Centers for Medicare and Medicaid Services. 
 
(2) The department shall establish a fee schedule for the list of pharmacist services. 
 
(3) The rate of reimbursement for pharmacist services shall be at 85 percent of the fee schedule 
for physician services under the Medi-Cal program. 
 
(b) (1) The following services are covered pharmacist services that may be provided to a Medi-
Cal beneficiary: 
 
(A) Furnishing travel medications, as authorized in clause (3) of subparagraph (A) of paragraph  
(10) of subdivision (a) of Section 4052 of the Business and Professions Code. 
(B) Furnishing naloxone hydrochloride, as authorized in Section 4052.01 of the Business and 
Professions Code. 
 
(C) Furnishing self-administered hormonal contraception, as authorized in subdivision (a) of 
Section 4052.3 of the Business and Professions Code. 
 
(D) Initiating and administering immunizations, as authorized in Section 4052.8 of the Business 
and Professions Code. 
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(E) Providing tobacco cessation counseling and furnishing nicotine replacement therapy, as 
authorized in Section 4052.9 of the Business and Professions Code. 
 
(F) Initiating and furnishing preexposure prophylaxis and postexposure prophylaxis, as 
authorized in Section 4052.02 of the Business and Professions Code. 
 
(2) Covered pharmacist services shall be subject to department protocols and utilization controls. 
 
(c) A pharmacist shall be enrolled as an ordering, referring, and prescribing provider under the 
Medi-Cal program prior to rendering a pharmacist service that is submitted by a Medi-Cal 
pharmacy provider for reimbursement pursuant to this section. 
 
(d) (1) The director shall seek any necessary federal approvals to implement this section. This 
section shall not be implemented until the necessary federal approvals are obtained and shall be 
implemented only to the extent that federal financial participation is available. 
 
(2) This section neither restricts nor prohibits any services currently provided by pharmacists as 
authorized by law, including, but not limited to, this chapter, or the Medicaid state plan. 
 
(e) Notwithstanding Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of 
Title 2 of the Government Code, the department may implement, interpret, or make specific this 
section, and any applicable federal waivers and state plan amendments, by means of all-county 
letters, plan letters, plan or provider bulletins, or similar instructions, without taking regulatory 
action. By July 1, 2021, the department shall adopt regulations in accordance with the 
requirements of Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 
of the Government Code. Commencing July 1, 2017, the department shall provide a status report 
to the Legislature on a semiannual basis, in compliance with Section 9795 of the Government 
Code, until regulations have been adopted. 
SEC. 5. 
No reimbursement is required by this act pursuant to Section 6 of Article XIII B of the California 
Constitution because the only costs that may be incurred by a local agency or school district will 
be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or 
changes the penalty for a crime or infraction, within the meaning of Section 17556 of the 
Government Code, or changes the definition of a crime within the meaning of Section 6 of 
Article XIII B of the California Constitution. 
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APPENDIX B  LITERATURE REVIEW METHODS 
This appendix describes methods used in the medical effectiveness literature review conducted for this 
report. A discussion of CHBRP’s system for grading evidence, as well as lists of MeSH Terms, publication 
types, and keywords, follows. 
CHBRP’s medical effectiveness review addressed: (1) the effectiveness of PrEP and PEP in preventing 
HIV/AIDS, (2) the impact of removing prior authorization and step therapy on the likelihood that health 
professionals with prescribing authority will prescribe PrEP and PEP, (3) the impact of removing prior 
authorization and step therapy on uptake and adherence of PrEP and PEP, (4) the ability of pharmacists 
to prescribe PrEP and PEP safely and effectively, and (5) any harms or adverse events associated with 
PrEP, PEP, or other HIV prevention therapies. Pertinent studies were identified through searches of 
PubMed, the Cochrane Library, Web of Science, Embase, and Scopus. The website for the Agency for 
Healthcare Research and Quality (AHRQ), an organization that produces systematic reviews and meta-
analyses, was also searched. 
The search was limited to abstracts of studies published in English and conducted in the United States 
and other developed countries. For studies related to the effectiveness of PrEP and PEP, the search was 
limited to studies published from 2018 to present because CHBRP had previously conducted thorough 
literature searches on these topics in 2018 for SB 1021. Because the analysis of SB 1021 did not address 
the impact of prior authorization or step therapy on prescription of PrEP or PEP or adherence to PrEP or 
PEP, the search for these studies was limited to 2012 to present. 2012 was chosen as the starting point 
because the FDA approved Truvada® for PrEP treatment in 2012. The search for articles on the safety 
and effectiveness of provision of PrEP and PEP by pharmacists was also limited to studies published 
from 2012 to present. The literature review also included articles on prior authorization and pharmacist 
prescribing published prior to 2012 that were recommended by the content expert and the peer faculty 
reviewer. 
The literature on the effectiveness of PrEP did not include any new randomized controlled trials (RCTs), 
although new information about medication adherence and dosing regimens, which can impact the 
effectiveness of PrEP, was described. One new study was an extension of an RCT that examined PrEP’s 
impact on patients’ self-perceived quality of life. The literature search on the effectiveness of PEP did not 
include any new studies. CHBRP found no studies on the impact of removing prior authorization and step 
therapy for PrEP or PEP but did include one study that analyzed prior authorization for HIV treatment. 
CHBRP identified only one observational study describing pharmacists’ ability to safely and effectively 
prescribe PrEP and also included one study on the safety and efficacy of pharmacists’ prescription of oral 
contraceptives. 
Reviewers screened the title and abstract of each citation retrieved by the literature search to determine 
eligibility for inclusion. The reviewers acquired the full text of articles that were deemed eligible for 
inclusion in the review and reapplied the initial eligibility criteria. 
Of the 557 articles found in the literature search, 27 were reviewed for potential inclusion, and 11 were 
included in the review of medical effectiveness for SB 159. The other articles were eliminated because 
they did not focus on therapies for HIV prevention, were of poor quality, or did not report findings from 
clinical research studies. While reviewing the 27 articles for potential inclusion, 8 articles cited by these 
articles were identified for potential inclusion, and 7 were included in this report. Based on 
recommendations from content experts, an additional 13 articles were reviewed for potential inclusion, 2 
of which were included. Eighteen references from CHBRP’s report on SB 1021 were also included in this 
report.  
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Evidence Grading System 
In making a “call” for each outcome measure, the medical effectiveness lead and the content expert 
consider the number of studies as well the strength of the evidence. Further information about the criteria 
CHBRP uses to evaluate evidence of medical effectiveness can be found in CHBRP’s Medical 
Effectiveness Analysis Research Approach.45 To grade the evidence for each outcome measured, the 
team uses a grading system that has the following categories: 
• Research design; 
• Statistical significance; 
• Direction of effect;  
• Size of effect; and 
• Generalizability of findings.  
The grading system also contains an overall conclusion that encompasses findings in these five domains. 
The conclusion is a statement that captures the strength and consistency of the evidence of an 
intervention’s effect on an outcome. The following terms are used to characterize the body of evidence 
regarding an outcome: 
• Clear and convincing evidence; 
• Preponderance of evidence; 
• Limited evidence 
• Inconclusive evidence; and  
• Insufficient evidence. 
A grade of clear and convincing evidence indicates that there are multiple studies of a treatment and that 
the large majority of studies are of high quality and consistently find that the treatment is either effective 
or not effective.  
A grade of preponderance of evidence indicates that the majority of the studies reviewed are consistent in 
their findings that treatment is either effective or not effective.  
A grade of limited evidence indicates that the studies had limited generalizability to the population of 
interest and/or the studies had a fatal flaw in research design or implementation. 
A grade of inconclusive evidence indicates that although some studies included in the medical 
effectiveness review find that a treatment is effective, a similar number of studies of equal quality suggest 
the treatment is not effective. 
A grade of insufficient evidence indicates that there is not enough evidence available to know whether or 
not a treatment is effective, either because there are too few studies of the treatment or because the 
available studies are not of high quality. It does not indicate that a treatment is not effective. 
Search Terms  
                                                     
45 Available at: http://chbrp.com/analysis_methodology/medical_effectiveness_analysis.php..  
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• Condom use  
• Darunavir 
• Dolutegravir 
• Drug uptake 
• HIV 
• HIV discordant  
• HIV exposure 
• HIV prevention 
• HIV transmission 
• Intravenous (IV) drug use 
• Multiple sexual partners 
• Multi-tablet regimen 
• PEP adherence  
• PEP prescription  
• Pre-exposure prophylaxis (PrEP) 
• Pregnancy 
• PrEP adherence  
• PrEP prescription  
• Prior authorization  
• Post-exposure prophylaxis (PEP) 
• Raltegravir 
• Ritonavir 
• Single tablet regimen 
• Step therapy  
• Treatment adherence 
• Treatment resistance 
• Truvada 
• Utilization management 
• Zidovudine 
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APPENDIX C  COST IMPACT ANALYSIS: DATA 
SOURCES, CAVEATS, AND ASSUMPTIONS 
The cost analysis in this report was prepared by the members of the cost team, which consists of CHBRP 
task force members and contributors from the University of California, Los Angeles, and the University of 
California, Davis, as well as the contracted actuarial firm, Milliman, Inc.46  
Information on the generally used data sources and estimation methods, as well as caveats and 
assumptions generally applicable to CHBRP’s cost impacts analyses are available at CHBRP’s website.47 
This appendix describes analysis-specific data sources, estimation methods, caveats and assumptions 
used in preparing this cost impact analysis. 
Analysis-Specific Caveats and Assumptions 
This section discusses the caveats and assumptions relevant to specifically to an analysis of SB 159’s 
provision regarding the coverage of medications for the prevention of HIV/AIDS. 
The population subject to the mandated offering includes enrollees in DMHC-regulated plans and CDI-
regulated policies for large-group, small-group, and individual marketplace plans, CalPERS plans, and 
enrollees receiving benefits through Medi-Cal Managed Care plans, County Organized Health Systems 
(COHS), and the fee-for-service (FFS) program. As discussed in the Policy Context section, preventive 
HIV medications are carved out of Medi-Cal Managed Care plans and COHS, and are provided through 
the FFS program.  
Baseline HIV prevention drug treatment Commercial costs and associated utilization were based on 2016 
MarketScan® and Milliman’s proprietary 2016 Consolidated Health Cost Guidelines Sources Database 
(CHSD) which contain Commercial claims, encounters, and enrollment data for the state of California. 
Because the potential impact change of this mandate affects those enrollees who use HIV drug for 
prevention purposes, the analysis was limited to enrollees that had not been diagnosed with HIV as of the 
date of the first HIV prevention drug usage in 2016.  
• CHBRP assumes that if an individual is diagnosed as HIV positive, he/she cannot become HIV 
negative in the future. This is done because some of the HIV prevention drugs are also used by 
HIV-positive enrollees for treatment purposes.  
• CHBRP expects that any mandate utilization changes from this component of the bill would be 
based on changes to current HIV prevention coverage. 
• CHBRP expects that the cost per prescription remains the same between premandate and 
postmandate. 
• CHBRP assumes that the mandate would not impact any forms of member cost sharing, such as 
deductibles, copays, and coinsurance. 
                                                     
46 CHBRP’s authorizing statute, available at http://chbrp.com/CHBRP%20authorizing%20statute_2018_FINAL.pdf, 
requires that CHBRP use a certified actuary or “other person with relevant knowledge and expertise” to determine 
financial impact.  
47 See method documents posted here, http://chbrp.com/analysis_methodology/cost_impact_analysis.php; in 
particular, see 2019 Cost Analyses: Data Sources, Caveats, and Assumptions. 
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• CHBRP assumes pharmacists that plan to complete the necessary training have completed it by 
January 1, 2020.  The credentialing programs required may not be fully operational by January 1, 
2020, so this assumption may overstate the impact for year 1. 
Tables 6 and 7 list the diagnosis codes used to identify HIV-positive enrollees and drug product names 
used to identify HIV prevention drugs, respectively. 
Prevention treatment of HIV used Healthcare Common Procedure Coding System (HCPCS) and Current 
Procedural Terminology (CPT) codes identified with carrier coverage guidelines and reviewed by a 
content expert. Additionally, drug prevention treatment of HIV used National Drug Codes (NDC) codes 
identified using the Truven Health Analytics Red Book™ and reviewed by a content expert. 
Table 6. Diagnosis Codes 
Diagnosis Codes (ICD 9 and ICD-10) Description 
B20 HIV disease 
042 HIV disease 
 
Table 7. List of Medications to Prevent HIV 
HIV Prevention Category Drug Product Name 
Pre-HIV exposure/post-HIV exposure Truvada 
Post-HIV exposure Darunavir 
Post-HIV exposure Dolutegravir 
Post-HIV exposure Raltegravir 
Post-HIV exposure Ritonavir 
Post-HIV exposure Zidovudine 
HIV prevention drug treatment users were categorized as pre-HIV exposure (PrEP) prevention and post-
HIV exposure prevention (PEP). The PrEP exposure regimen is a single-tab Truvada® pill daily. The 
acute PEP prescription is a 28-day regimen of multitablet combination of NRTIs and integrase inhibitors. 
One or more of the post-HIV exposure drugs can also be used for acute exposure treatment. The majority 
of providers prescribe multi-drug PEP for all exposures (guidelines generally suggest that more than one 
of the post-HIV exposure drugs should be used, e.g., Truvada plus another drug), however clinicians 
experienced in PEP management may on occasion prescribe a modified regimen (e.g., Truvada only for 
PEP for lower risk exposure). Because Truvada-only is rarely used for PEP, CHBRP assumed Truvada-
only users observed in the MarketScan and CHSD datasets were PrEP exposure prevention treatment 
users. If an HIV-negative enrollee uses at least one of the post-HIV exposure exclusive drugs (not 
Truvada), that user is considered a post-exposure user for the remainder of the year. Another post-
exposure prevention strategy addresses fetal exposure during pregnancy and birth. In general, this 
requires the baby receive a 4- to 6-week course of zidovudine, which is on occasion (but rarely) used in 
combination with another drug. 
Baseline prescription drug unit costs were trended at an annual rate of 6.2% from 2016 to 2020 based on 
the “2017 Drug Trend Report” by Express Scripts for HIV drugs and recent Truvada trend. The 6.2% 
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trend represents the 2017 HIV drug trends for the commercial population represented within the report. 
The analysis assumes that the unit cost per drug does not change postmandate. 
Additionally, lab tests are required both prior to prescribing HIV PrEP or PEP and on a quarterly basis for 
monitoring purposes.  Table 8 lists the lab tests assumed to be associated with the provision or 
monitoring of HIV PrEP and PEP. 
Table 8. List of Lab Tests for Provision or Monitoring of HIV PrEP and PEP 
CPT Code Description 
80047 Metabolic panel ionized ca 
80048 Metabolic panel total ca 
80053 Comprehen metabolic panel 
80069 Renal function panel 
80074 Acute hepatitis panel 
82565 Assay of creatinine 
86689 Htlv/hiv confirm antibody 
86701 HIV-1 antibody 
86702 HIV-2 antibody 
86703 Hiv-1/hiv-2 result antibody 
86704 Hep b core antibody total 
86705 Hep b core antibody igm 
86705 Hep b surface antibody 
87340 Hepatitis b surface ag ai 
87341 Hepatitis b surface ag ia 
87389 Hiv-1 ag w/hiv-1 & hiv-2 ab 
87390 Hiv-1 ag ia 
87391 Hiv-2 ag ia 
87517 Hepatitis b dna quant 
87534 Hiv-1 dna dir probe 
87535 Hiv-1 probe&reverse trnscrpj 
87536 Hiv-1 quant&revrse trnscrpj 
87537 Hiv-2 dna dir probe 
87538 Hiv-2 probe&revrse trnscripj 
87539 Hiv-2 quant&revrse trnscripj 
87900 Phenotype infect agent drug 
87901 Genotype DNA HIV reverse t 
87912 Genotype DNA hepatitis b 
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Baseline lab test unit costs were trended at an annual rate of 2% from 2016 to 2020, based on the 
December 2018 medical component of CPI. 
The analysis assumed that utilization rates per 1,000 enrollees change postmandate only due to 
increased access. Baseline utilization rates per 1,000 were developed based on MarketScan and CHSD 
data for members not diagnosed with HIV and who also use the HIV prevention drugs.  Baseline 
utilization was estimated to increase 2% postmandate due to the increased access. 
Carrier surveys were administered to estimate the percentage of enrollees who had HIV-outpatient drug 
prevention coverage. Results from the CHBRP current coverage questionnaire for health plans and 
insurers indicate 100% on-formulary coverage for HIV PrEP and PEP, respectively. Carrier surveys also 
indicated that there was no pre-authorization or step therapy protocols for HIV PrEP and PEP.  Therefore, 
no additional utilization changes were modeled. 
Determining Public Demand for the Proposed Mandate 
This subsection discusses public demand for the benefits SB 159 would mandate. Considering the criteria 
specified by CHBRP’s authorizing statute, CHBRP reviews public demand for benefits relevant to a 
proposed mandate in two ways. CHBRP:  
• Considers the bargaining history of organized labor; and 
• Compares the benefits provided by self-insured health plans or policies (which are not regulated 
by the DMHC or CDI and therefore not subject to state-level mandates) with the benefits that are 
provided by plans or policies that would be subject to the mandate. 
On the basis of conversations with the largest collective bargaining agents in California, CHBRP 
concluded that unions currently do not include cost-sharing arrangements for description treatment or 
service. In general, unions negotiate for broader contract provisions such as coverage for dependents, 
premiums, deductibles, and broad coinsurance levels. 
Among publicly funded self-insured health insurance policies, the preferred provider organization (PPO) 
plans offered by CalPERS currently have the largest number of enrollees. The CalPERS PPOs currently 
provide benefit coverage similar to what is available through group health insurance plans and policies 
that would be subject to the mandate.  
To further investigate public demand, CHBRP used the bill-specific coverage survey to ask carriers who 
act as third-party administrators for (non-CalPERS) self-insured group health insurance programs 
whether the relevant benefit coverage differed from what is offered in group market plans or policies that 
would be subject to the mandate. The responses indicated that there were no substantive differences.  
Second Year Impacts on Benefit Coverage, Utilization, and Cost 
In order to develop Table 9, CHBRP has considered whether continued implementation during the 
second year of the benefit coverage requirements of SB 159 would have a substantially different impact 
on utilization of either the tests, treatments or services for which coverage was directly addressed, the 
utilization of any indirectly affected utilization, or both. To generate this table, CHBRP reviewed the 
literature and consulted content experts about the possibility of varied second year impacts and applied 
what was learned to a projection of a second year of implementation.   
As displayed in Table 9, the second year’s impacts of SB 159 would be substantially the same as the 
impacts in the first year (see Table 1). 
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Table 9. SB 159 Impacts on Benefit Coverage, Utilization, and Cost, 2021 
  Baseline Postmandate Increase/ 
Decrease 
Percentage 
Change 
Benefit coverage 
 Total enrollees with 
health insurance 
subject to state-level 
benefit mandates (a)  
24,395,000 24,395,000 
0 0% 
 Total enrollees with 
health insurance 
subject to SB 159 (b) 
100% 100% 0% 0% 
 Total percentage of 
enrollees with coverage 
for PrEP and PEP 
without prior 
authorization and step 
therapy 
100% 100% 0% 0% 
 Total percentage of 
enrollees able to obtain 
PrEP and PEP directly 
from pharmacist 
0% 100% 100% 100% 
Utilization and unit cost 
 Number of enrollees 
using PrEP 
 32,322   32,968   646  2% 
 Number of enrollees 
using PEP 
 6,658   6,791   133  2% 
 Scripts per user of 
PrEP 
 6.002   6.002  0.000 0% 
 Scripts per user of PEP 
(c) 
 10.410   10.410  0.000 0% 
 Average prescription 
drug regime cost per 
user (PrEP and PEP) 
$14,679.22 $14,679.22 $0.00 0% 
 Average number of lab 
tests per user of PrEP 
 3.597   3.597  0.000 0% 
 Average number of lab 
tests per user of PEP 
 2.534   2.534  0.000 0% 
 Average annual cost of 
lab tests per user of 
PrEP 
$142.08 $142.08 $0.00 0% 
 Average annual cost of 
lab tests per user of 
PEP 
$159.92 $159.92 $0.00 0% 
Expenditures 
Premiums by payer 
 Private employers for 
group insurance 
$90,700,422,000 $90,709,715,000 $9,293,000 $90,700,422,000 
 CalPERS HMO 
employer expenditures 
(d) 
$3,234,903,000 $3,235,195,000 $292,000 $3,234,903,000 
 Medi-Cal Managed 
Care Plan expenditures 
$29,186,401,000 $29,186,401,000 $0 $29,186,401,000 
 Enrollees with 
individually purchased 
insurance 
$13,111,153,000 $13,113,109,000 $1,956,000 $13,111,153,000 
 Enrollees with group 
insurance, CalPERS 
HMOs, Covered 
$15,255,718,000 $15,257,401,000 $1,683,000 0.0110% 
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California, and Medi-
Cal Managed Care (e) 
Enrollee expenses 
 For covered benefits 
(deductibles, 
copayments, etc.) 
$15,636,259,000 $15,636,812,000 $553,000 0.0035% 
 For noncovered 
benefits (f) 
$0 $0 $0 0.00% 
Total expenditures $167,124,856,000 $167,138,633,000 $13,777,000 0.0082% 
Source: California Health Benefits Review Program, 2019. 
Notes: Provision of PrEP and PEP are “carved out” of Medi-Cal Managed Care plans and COHS and are instead provided through 
the fee-for-service program.  There are approximately 10,545,000 enrollees in full-scope Medi-Cal in 2020. Although not shown in 
Table 1, CHBRP estimates that utilization of PrEP will increase from 9000 baseline to 9,180 postmandate (2% utilization increase).  
The increase in utilization is estimated to increase state Medi-Cal expenditures $1,256,539. CHBRP is unable to estimate utilization 
changes of PEP due to lack of data. Impacts in 2021 would be similar to the impacts projected in 2020.  
 (a) Enrollees in plans and policies regulated by DMHC or CDI aged 0 to 64 years as well as enrollees 65 years or older in 
employer-sponsored health insurance. This group includes commercial enrollees (including those associated with Covered 
California or CalPERS) and Medi-Cal beneficiaries enrolled in DMHC-regulated plans.48  
(b) Health insurance that has no OPD benefit or has an OPD benefit not regulated by DMHC or CDI is considered compliant.49 
(c) Occupational PEP may be covered through worker’s comp and therefore would not appear in this claims data. As a result, 
utilization of PEP may be higher on a per-person basis due to the nature of non-occupational exposure and the likelihood of repeat 
exposure. 
(d) Approximately 56.17% of CalPERS enrollees in DMHC-regulated plans are state retirees, state employees, or their dependents. 
About one in five (20.5%) of these enrollees has a pharmacy benefit not subject to DMHC.50  CHBRP has projected no impact for 
those enrollees.  However, CalPERS could, postmandate, require equivalent coverage for all its members (which could increase the 
total impact on CalPERS). 
(e) Enrollee premium expenditures include contributions by employees to employer-sponsored health insurance, health insurance 
purchased through Covered California, and contributions to Medi-Cal Managed Care. 
(f) Includes only those expenses that are paid directly by enrollees to providers for services related to the mandated benefit that are 
not currently covered by insurance. In addition, this only includes those expenses that will be newly covered, postmandate. Other 
components of expenditures in this table include all health care services covered by insurance. 
Key: CalPERS  = California Public Employees’ Retirement System; CDI = California Department of Insurance; DMHC = Department 
of Managed Health Care; HMO = Health Maintenance Organizations; OPD = Outpatient Prescription Drug; PEP = post-exposure 
prophylaxis; PrEP = pre-exposure prophylaxis.  
 
                                                     
48 For more detail, see Estimates of Sources of Health Insurance in California, available at 
http://chbrp.com/analysis_methodology/cost_impact_analysis.php.   
49 For more detail, see Estimates of Pharmacy Benefit Coverage, available at 
http://chbrp.com/analysis_methodology/cost_impact_analysis.php). 
50 For more detail, see Estimates of Pharmacy Benefit Coverage, available at 
http://chbrp.com/analysis_methodology/cost_impact_analysis.php).   
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